Anti-TREM2 antibody therapy for fibrosis

Anti-TREM2 antibodies target TREM2+ bone marrow cells to address the lack of effective treatments for liver fibrosis and cirrhotic sarcopenia, enhancing the immune response and reducing fibrosis to improve patient outcomes and transplantation success.

JP2024542618AInactive Publication Date: 2024-11-15PIONYR IMMUNOTHERAPEUTICS INC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024531629
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-29
Filing Date
2022-11-29
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for liver fibrosis and cirrhosis, such as nonalcoholic steatohepatitis (NASH), lack effective pharmacological interventions, and cirrhotic sarcopenia poses significant challenges in liver transplantation due to muscle wasting and increased complications, with lifestyle changes being the only available option.

Method used

Administration of anti-TREM2 antibodies that bind to TREM2 protein, specifically targeting TREM2+ bone marrow cells to deplete or inhibit their function, thereby modulating the immune response and reducing fibrosis.

Benefits of technology

The anti-TREM2 antibodies effectively reduce liver fibrosis and cirrhotic sarcopenia by enhancing the immune response, potentially improving patient outcomes and increasing the chances of successful liver transplantation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542618000001_ABST
    Figure 2024542618000001_ABST
Patent Text Reader

Abstract

Provided herein are anti-TREM2 antibodies, as well as related methods of making and using the anti-TREM2 antibodies. Also provided herein are methods and compositions for enhancing an immune response and / or treating an immune-related condition, such as a fibrotic disease, in an individual, including using an anti-TREM2 antibody or antigen-binding fragment thereof to kill, neutralize, or deplete unstimulated bone marrow cells.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 63 / 283,738, filed November 29, 2021, which is incorporated by reference in its entirety.

[0002] Sequence Listing This application contains a Sequence Listing, which has been submitted electronically in XML format and is incorporated by reference in its entirety. The Sequence Listing XML file described above was created on November 15, 2022, is named PII-014WO_SL.xml, and is 55,804 bytes in size. [Background technology]

[0003] background An estimated 600,000 individuals in the United States suffer from cirrhosis, with 14,000 of these patients having end-stage disease and awaiting liver transplantation. Studies suggest that up to 40-60% of patients with cirrhosis have muscle wasting. The resulting frailty is a prominent cause of functional decline, cirrhosis-related complications, hospitalization, and mortality in patients with end-stage liver disease (ESLD). Liver transplantation is the definitive treatment for ESLD, but physical functional decline, independent of liver disease severity, is associated with an increased risk of being removed from the transplant waiting list. An estimated 40-50% of patients with cirrhosis present with cirrhotic sarcopenia. Cirrhotic sarcopenia is a frequent complication in cirrhosis that adversely impacts patient survival and quality of life. Cirrhotic sarcopenia is a systemic disease resulting from hyperammonemia due to dysfunction of the urea cycle in cirrhosis, resulting in impaired muscle mass, although muscles detoxify ammonia. Sarcopenia reduces survival, decreases chances of receiving transplants, and increases the risk of cirrhosis-related complications in patients with cirrhosis. The current standard of care for patients with cirrhosis, such as those with ESLD or cirrhotic sarcopenia, includes lifestyle modifications such as increased exercise and dietary interventions. At present, there are no approved pharmacological interventions.

[0004] Nonalcoholic fatty liver disease (NAFLD) has a worldwide prevalence of 25% and is the leading cause of cirrhosis and hepatocellular carcinoma (HCC). NAFLD encompasses a continuum of disease ranging from steatosis with or without mild inflammation (nonalcoholic fatty liver) to nonalcoholic steatohepatitis (NASH), characterized by necroinflammation and rapid fibrotic progression. NAFLD is bidirectionally associated with components of the metabolic syndrome, and type 2 diabetes increases the risk of cirrhosis and related complications. Chronic liver injury in NASH significantly increases the risk of end-stage liver disease, such as cirrhosis and liver cancer. Progressive liver fibrosis is a risk factor for liver-related outcomes and overall mortality and can be assessed with a combination of noninvasive tests. Patients with NASH are at increased risk of developing hepatocellular carcinoma (HCC).

[0005] Lifestyle modification and weight loss are currently the only options for preventing and treating NAFLD. There is no approved medical therapy for NAFLD, but several drugs are in advanced stages of development. Therefore, additional therapies are needed to treat liver fibrosis and NAFLD.

[0006] In normal tissues, many myeloid cells, such as macrophages, are useful for the proper functioning of both innate and adaptive immunity, especially wound repair. Recently, a new scar-associated TREM2+CD9+ macrophage subpopulation was identified, which was shown to expand in liver fibrosis, differentiate from circulating monocytes, and be fibrogenic. Ramachandran et al. Nature. 2019 November; 575(7783): 512-518 (Non-Patent Document 1).

[0007] Related patents and patent applications include PCT / US2015 / 052682, filed September 28, 2015, PCT / US2016 / 054104, filed September 28, 2016, and USPN 10,836,828, each of which is incorporated by reference in its entirety for all purposes.

[0008] All patents, patent applications, publications, documents, and articles cited herein are hereby incorporated by reference in their entirety. [Prior art documents] [Patent documents]

[0009] [Patent Document 1] PCT / US2015 / 052682 [Patent Document 2] PCT / US2016 / 054104 [Patent Document 3] USPN10,836,828 [Non-patent literature]

[0010] [Non-Patent Document 1] Ramachandran et al.Nature.2019 November;575(7783):512-518 Summary of the Invention

[0011] overview Described herein is a method of treating a fibrotic disease in a subject, the method comprising administering to the subject an isolated antibody that binds to human TREM2 (SEQ ID NO: 15) and optionally competes with the 37017 antibody (SEQ ID NOs: 31 and 32) for binding to mouse TREM2 (SEQ ID NO: 17).

[0012] In some embodiments, the antibody comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO:9, a CDR-H2 comprising the sequence set forth in SEQ ID NO:10, a CDR-H3 comprising the sequence set forth in SEQ ID NO:11, a CDR-L1 comprising the sequence set forth in SEQ ID NO:12, a CDR-L2 comprising the sequence set forth in SEQ ID NO:13, and a CDR-L3 comprising the sequence set forth in SEQ ID NO:14.

[0013] In some embodiments, the antibody is defucosylated and comprises the VH sequence set forth in SEQ ID NO:1, the VL sequence set forth in SEQ ID NO:2, and an active human IgG1 Fc region.

[0014] In some embodiments, the antibody comprises the VH sequence set forth in SEQ ID NO:1, the VL sequence set forth in SEQ ID NO:2, and a human Fc-silent region (optionally having an IgG1 or IgG4 isotype, and optionally containing the N297Q mutation).

[0015] In some embodiments, the antibody comprises all three heavy chain CDRs of the sequence shown in SEQ ID NO:7 and all three light chain CDRs of the sequence shown in SEQ ID NO:8.

[0016] In some embodiments, the antibody comprises an A to T substitution at position 97 of the sequence set forth in SEQ ID NO:7 and a K to R substitution at position 98 of the sequence set forth in SEQ ID NO:7.

[0017] In some embodiments, the antibody comprises a VH sequence as shown in SEQ ID NO:1, 3, or 5.

[0018] In some embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO:1, 3, or 5 and a VL sequence set forth in SEQ ID NO:2, 4, or 6.

[0019] In some embodiments, the antibody comprises the VH sequence shown in SEQ ID NO:1.

[0020] In some embodiments, the antibody comprises the VH sequence set forth in SEQ ID NO:1 and the VL sequence set forth in SEQ ID NO:2.

[0021] In some embodiments, the antibody is the 37012 antibody.

[0022] In some embodiments, the antibody comprises a heavy chain sequence set forth in SEQ ID NO:25 and a light chain sequence set forth in SEQ ID NO:26.

[0023] In another aspect, described herein is an isolated antibody that binds to human TREM2 (SEQ ID NO: 15), wherein the antibody competes with the 37017 antibody (SEQ ID NOs: 31 and 32) for binding to mouse TREM2 (SEQ ID NO: 17), and comprises an active human Fc region.

[0024] In some embodiments, the antibody is human, humanized, or chimeric.

[0025] In some embodiments, the antibody is humanized.

[0026] In some embodiments, the antibody has a titer of about 1, 2, 3, 4, or 5×10 as measured by a surface plasmon resonance (SPR) assay. -9 The following K D Binds to human TREM2 at

[0027] In some embodiments, the antibodies are capable of specifically killing, depleting or neutralizing TREM2+ bone marrow cells, optionally unstimulated bone marrow cells.

[0028] In some embodiments, the antibody has antibody-dependent cell-mediated cytotoxicity (ADCC) activity. In some embodiments, the antibody has antibody-mediated cellular phagocytosis (ADCP) activity. In some embodiments, the antibody has complement-dependent cytotoxicity (CDC) activity.

[0029] In some embodiments, the antibodies kill, disable, or deplete myeloid cells through antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-mediated cellular phagocytosis (ADCP) activity, or complement-dependent cytotoxicity (CDC).

[0030] In some embodiments, the antibody is at least one of a monoclonal antibody, a neutral antibody, an antagonist antibody, an agonist antibody, a polyclonal antibody, an IgG1 antibody, an IgG3 antibody, a defucosylated antibody, a bispecific antibody, a human antibody, a chimeric antibody, a full-length antibody, and an antigen-binding fragment thereof.

[0031] In some embodiments, the antibody is a monoclonal antibody.

[0032] In some embodiments, the antibody is multispecific.

[0033] In some embodiments, the antibody is defucosylated.

[0034] In some embodiments, an antibody is an antigen-binding fragment thereof, such as a Fab, Fab', F(ab') 2 , Fv, scFv, (scFv) 2 , a single chain antibody molecule, a dual variable domain antibody, a single variable domain antibody, a linear antibody, or a V domain antibody.

[0035] In some embodiments, the antibody comprises a scaffold, optionally the scaffold is an Fc, optionally a human Fc.

[0036] In some embodiments, the antibody comprises a heavy chain constant region of a class selected from IgG, IgA, IgD, IgE, and IgM.

[0037] In some embodiments, the antibody comprises a heavy chain constant region of the class IgG and a subclass selected from IgG1, IgG2, IgG3, and IgG4.

[0038] In some embodiments, the antibody comprises an IgG1 heavy chain constant region.

[0039] In some embodiments, the Fc comprises one or more modifications that result in increased half-life, increased ADCC activity, increased ADCP activity, or increased CDC activity compared to an Fc that does not contain the one or more modifications.

[0040] In some embodiments, the Fc binds to an Fcγ receptor selected from the group consisting of FcγRI, FcγRIIa, FcγRIIb, FcγRIIc, FcγRIIIa, and FcγRIIIb.

[0041] In another aspect, described herein is an isolated antibody for use in treating a fibrotic disease.

[0042] In another aspect, described herein are isolated antibodies that compete with the antibodies described herein for binding to human TREM2.

[0043] In another aspect, described herein is an isolated antibody that binds to the human TREM2 epitope bound by an antibody described herein.

[0044] In another aspect, the antibody described herein, its V H , that V L Described herein is an isolated polynucleotide or set of polynucleotides, optionally cDNA, encoding the antibody, its light chain, its heavy chain, or an antigen-binding portion thereof.

[0045] In another aspect, described herein is a vector or set of vectors comprising a polynucleotide or set of polynucleotides described herein.

[0046] In another aspect, described herein is a host cell comprising a polynucleotide or set of polynucleotides described herein, or a vector or set of vectors described herein.

[0047] In another aspect, described herein is a method of producing an antibody comprising expressing the antibody by a host cell described herein and isolating the expressed antibody.

[0048] In another aspect, described herein is a pharmaceutical composition comprising an antibody described herein and a pharma- ceutically acceptable excipient.

[0049] In another aspect, methods are described herein for treating or preventing a fibrotic disease or condition in a subject in need thereof, comprising administering to the subject, e.g., an effective amount of an antibody or pharmaceutical composition that binds to TREM2 as described herein.

[0050] In some embodiments, the disease or condition is liver disease. In some embodiments, killing, disabling or depleting unstimulated bone marrow cells treats liver disease. In some embodiments, the liver disease is fibrosis, non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH). In some embodiments, the disease is not cancer.

[0051] In some embodiments, the antibodies kill, neutralize, or deplete myeloid cells through antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-mediated cellular phagocytosis (ADCP) activity, or complement-dependent cytotoxicity (CDC). In some embodiments, the antibodies have receptor ligand blocking activity, agonism activity, or antagonist activity.

[0052] In some embodiments, the subject is a human.

[0053] In some embodiments, the contacting enhances an immune response in the subject. In some embodiments, the enhanced immune response is an adaptive immune response. In some embodiments, the enhanced immune response is an innate immune response.

[0054] In some embodiments, the antibody kills bone marrow cells by at least one of ADCC, CDC, and ADCP. In some embodiments, the antibody neutralizes bone marrow cells by at least one of ADCC, CDC, and ADCP. In some embodiments, the antibody depletes bone marrow cells by at least one of ADCC, CDC, and ADCP. In some embodiments, the antibody has antibody-dependent cell-mediated cytotoxicity (ADCC) activity. In some embodiments, the antibody has complement-dependent cytotoxicity (CDC) activity. In some embodiments, the antibody has antibody-mediated phagocytosis (ADCP) activity. In some embodiments, the antibody has receptor ligand blocking activity, agonism activity, or antagonism activity.

[0055] In some embodiments, the bone marrow cells are stimulated bone marrow cells. In some embodiments, the bone marrow cells are unstimulated bone marrow cells. In some embodiments, the bone marrow cells include at least one of a dendritic cell, a tumor associated macrophage (TAM), a neutrophil, or a monocyte. In some embodiments, the bone marrow cells are neutrophils. In some embodiments, the bone marrow cells are tumor associated macrophages. In some embodiments, the bone marrow cells are in a population of immune cells that includes stimulated and unstimulated bone marrow cells. In some aspects, the bone marrow cells are TREM2+ bone marrow cells. In some aspects, the TREM2+ bone marrow cells include at least one of a TREM2+ macrophage, a TREM2+CD9+ macrophage, a macrophage, a scar associated macrophage (SAM), a dendritic cell, a tumor associated macrophage (TAM), a neutrophil, or a monocyte.

[0056] In some embodiments, the contacting enhances an immune response in the subject. In some embodiments, the enhanced immune response is an adaptive immune response. In some embodiments, the enhanced immune response is an innate immune response.

[0057] In some embodiments, the subject has previously undergone, is concurrently undergoing, or will subsequently undergo immunotherapy.

[0058] In another aspect, described herein is a method of killing, disabling or depleting TREM2+ bone marrow cells in a subject having a fibrotic disease, comprising contacting the bone marrow cells with an anti-TREM2 antibody (e.g., as described herein) or a pharmaceutical composition described herein.

[0059] In some embodiments, killing, disabling or depleting unstimulated bone marrow cells treats fibrosis by enhancing the immune response against the fibrotic disease.

[0060] In another aspect, described herein is a method of detecting TREM2 in a subject having or suspected of having a disease or condition, the method comprising: (a) receiving a sample from the subject; and (b) detecting the presence or level of TREM2 in the sample by contacting the sample with an antibody described herein.

[0061] In some embodiments, the disease or condition is a liver disease.

[0062] In another aspect, described herein is a kit comprising an antibody or pharmaceutical composition disclosed herein and instructions for use. [Brief description of the drawings]

[0063] [Figure 1]In addition to H&E staining, tissues were also stained for macrophages using anti-CD68. The intracellular marker CD68 is widely used in the literature as a reliable cytochemical marker for immunostaining monocytes / macrophages in inflamed tissues and tumors. No discernible changes in the number of CD68+ macrophages were observed in the lung (panel E) or in the other tissues analyzed compared to controls in any of the treatment groups, indicating that anti-TREM2-mediated depletion occurred specifically in the TME.

[0064] [Figure 2A] Anti-CD68 staining of FFPE lung tissue from the indicated treatment groups. [Figure 2B] Eight to nine fields from each section were used for quantification by light microscopy.

[0065] [Figure 3-1] Cells in selected tissues had absent or very low TREM2 expression. Shaded histograms are from TREM2KO and open histograms are from wild-type mice. The antibody used for anti-TREM2 staining was clone 237920 from R&D Systems. [Figure 3-2] See description of Figure 3-1.

[0066] [Figure 4] Cell surface expression of TREM2 (white histograms) was significantly higher in TAMs compared to granulocytic or monocytic MDSCs in both MC38 and CT26 tumors. Lymphocytes do not express TREM2. Isotype control staining is shown in grey filled histograms.

[0067] [Diagram 5]Cell surface expression of TREM2 (white histograms) was significantly higher in CD14-derived macrophages compared to any PBMC subset. Human PBMCs or macrophages were surface stained for either TREM2 (white histograms) or isotype control (grey histograms). PBMC subsets were identified as neutrophils, monocytes, or T cells using a pre-validated multicolor FACS panel.

[0068] [Figure 6] Cell surface expression of TREM2 (white histograms) was significantly higher in TAMs compared to other infiltrates or non-CD45 positive cells. Single cell suspensions from human tumor tissues were surface stained for either TREM2 (white histograms) or isotype control (grey histograms). Immune and non-immune subsets were identified using a pre-validated multicolor FACS panel.

[0069] [Figure 7] Percent relative cytotoxicity, as measured by lactate dehydrogenase (LDH) release, was significantly higher in target HEK-293 cells treated with defucosylated anti-TREM2 mAb (PI37012) compared to cells treated with isotype control Ab across multiple Ab concentrations.

[0070] [Figure 8] Relative luminescence, measuring NFAT reporter activity as a surrogate for ADCC induction, showed a dose-dependent increase in cells treated with increasing concentrations of defucosylated anti-TREM2 mAb (Afuc-PI-7012) and non-defucosylated anti-TREM2 mAb (PI-7012). No measurable relative luminescence was observed in cells treated with any concentration of Fc-silenced mAb.

[0071] [Figure 9]The left panel provides H&E staining of mouse liver cells after treatment with isotype control IgG2a antibody or defucosylated anti-TREM2 mAb (Afuc-PI-7012). The right panel provides collagen reduction in mouse liver after treatment with isotype control IgG2a antibody, defucosylated anti-TREM2 mAb (Afuc-PI-7012), or OCA. A statistically significant reduction in fibrosis (****p<0.0001) was observed in mice treated with defucosylated anti-TREM2 mAb (Afuc-PI-7012) compared to untreated or IgG2a-treated mice. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0072] Detailed Description For purposes of interpreting this specification, the following definitions shall apply and whenever appropriate, terms used in the singular shall include the plural and vice versa. In the event that a definition set forth below conflicts with a document incorporated herein by reference, the set forth definition shall control.

[0073] It is understood that aspects and embodiments of the invention described herein include "comprising," "consisting," and "consisting essentially of" aspects and embodiments.

[0074] For all compositions described herein and all methods of using the compositions described herein, the composition can include or "consist essentially of" the recited components or steps. When a composition is described as "consisting essentially of" a recited component, the composition contains the recited components and may contain other components that do not substantially affect the condition being treated, but does not contain other components that substantially affect the condition being treated other than the components explicitly recited, or if the composition does not contain extra components other than the recited components that substantially affect the condition being treated, the composition does not contain the extra components in a concentration or amount sufficient to substantially affect the condition being treated. When a method is described as "consisting essentially of" a recited step, the method may include the recited steps and may include other steps that do not substantially affect the condition being treated, but the method does not contain other steps that substantially affect the condition being treated other than those steps explicitly recited. As a non-limiting example, when a composition is described as "consisting essentially of" a component, the composition may further include any amount of a pharma- ceutically acceptable carrier, vehicle, or diluent, and other such components that do not substantially affect the condition being treated.

[0075] The term "optionally," when used consecutively, means the inclusion of one to all of the listed combinations, and contemplates all subcombinations.

[0076] As used herein, an "effective amount" or a "therapeutically effective amount" refers to an amount of a therapeutic compound, such as an anti-TREM2 antigen binding agent or anti-TREM2 antibody, administered to an individual, either in a single dose or as part of a series of doses, that is effective to produce or contribute to a desired therapeutic effect, either alone or in combination with another therapeutic modality. Examples of desired therapeutic effects are enhanced immune response, stabilization of disease, and amelioration of one or more symptoms. An effective amount may be given in one or more dosages.

[0077] The term "treating" as used herein refers to slowing or reversing the progression of a condition. The term "treating" as used herein also refers to slowing or reversing the progression of a condition, such as a fibrotic disease. The term "treatment" as used herein also refers to the act of treating a condition, such as a fibrotic disease.

[0078] Fibrotic disease or fibrosis is the accumulation of extracellular matrix molecules. This accumulation can constitute scar tissue or scarred areas, which are a common feature of chronic tissue damage. Examples of fibrosis include pulmonary fibrosis, renal fibrosis, and liver cirrhosis. Organs that may be affected by fibrosis include the liver, lungs, kidneys, and skin. Fibrotic disease can include liver disease, such as NASH.

[0079] As used herein, "individual" or "subject" refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sport, or pet animals such as dogs, horses, rabbits, cows, pigs, hamsters, otters, mice, ferrets, rats, cats, etc. In some embodiments, the individual is a human. In some embodiments, the individual is a mouse.

[0080] The terms "modulate" and "modulation" refer to decreasing or inhibiting, or alternatively, activating or increasing, the recited variable.

[0081] The terms "increase" and "activate" refer to a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold or greater increase in the recited variable.

[0082] The terms "reduce" and "inhibit" refer to a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold or greater decrease in the recited variable.

[0083] The term "agonize" refers to the activation of receptor signaling to induce a biological response associated with receptor activation. An "agonist" is an entity that binds to and agonizes a receptor.

[0084] The term "antagonize" refers to the inhibition of receptor signaling to inhibit a biological response associated with receptor activation. An "antagonist" is an entity that binds to and antagonizes a receptor.

[0085] The term "about" as used herein refers to the normal error range of the respective value, which is readily understood by those skilled in the art. An exemplary error range is ±5%. Reference herein to "about" a value or parameter includes (and describes) embodiments that are directed to the value or parameter itself.

[0086] It must be noted that as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0087] For any of the structural and functional properties described herein, methods for determining these properties are known in the art.

[0088] antibody structure The present application provides antibodies and compositions, including antibodies that bind to TREM2 protein, including antibodies that neutralize unstimulated bone marrow cells.

[0089] The term "antibody" is used herein in its broadest sense and includes a specific type of immunoglobulin molecule that contains one or more antigen-binding domains that specifically bind to an antigen or epitope. Antibodies specifically include intact antibodies (e.g., intact immunoglobulins), antibody fragments, and multispecific antibodies.

[0090] Recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. The "class" of an antibody or immunoglobulin refers to the type of constant domain or region carried by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these are further subdivided into subclasses (isotypes), e.g., IgG1, IgG2, 2 , IgG 3 , IgG 4 , IgA1, and IgA 2 The heavy-chain constant domains that correspond to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.

[0091] An exemplary immunoglobulin (antibody) structural unit is composed of two pairs of polypeptide chains, each pair having one "light" chain (about 25 kD) and one "heavy" chain (about 50-70 kD). The N-terminal domain of each chain defines a variable region of about 100-110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (VL) and variable heavy chain (VH) refer to these light and heavy chain domains, respectively. The IgG1 heavy chain comprises, from the N-terminus to the C-terminus, the VH, CH1, CH2, and CH3 domains, respectively. The light chain comprises, from the N-terminus to the C-terminus, the VL domain and the CL domain. The IgG1 heavy chain comprises a hinge between the CH1 and CH2 domains. In certain embodiments, the immunoglobulin construct comprises at least one immunoglobulin domain from IgG, IgM, IgA, IgD, or IgE connected to a therapeutic polypeptide. In some embodiments, the immunoglobulin domains found in the antibodies provided herein are from or derived from immunoglobulin-based constructs such as diabodies or nanobodies. In certain embodiments, the immunoglobulin constructs described herein comprise at least one immunoglobulin domain from a heavy chain antibody, such as a camelid antibody. In certain embodiments, the immunoglobulin constructs provided herein comprise at least one immunoglobulin domain from a mammalian antibody, such as a bovine antibody, a human antibody, a camelid antibody, a murine antibody, or any chimeric antibody.

[0092] In some embodiments, the antibodies provided herein comprise a heavy chain. In one embodiment, the heavy chain is IgA. In one embodiment, the heavy chain is IgD. In one embodiment, the heavy chain is IgE. In one embodiment, the heavy chain is IgG. In one embodiment, the heavy chain is IgM. In one embodiment, the heavy chain is IgG1. In one embodiment, the heavy chain is IgG2. In one embodiment, the heavy chain is IgG3. In one embodiment, the heavy chain is IgG4. In one embodiment, the heavy chain is IgA1. In one embodiment, the heavy chain is IgA2.

[0093] The term "hypervariable region" or "HVR" as used herein refers to each region of an antibody variable domain that is hypervariable in sequence and / or forms a structurally defined loop ("hypervariable loop"). Generally, a naturally occurring four-chain antibody comprises six HVRs, three in the VH (H1, H2, H3) and three in the VL (L1, L2, L3). HVRs generally comprise amino acid residues from the hypervariable loops and / or complementarity determining regions (CDRs), the latter being of highest sequence variability and / or involved in antigen recognition. With the exception of CDR1 in VH, CDRs generally comprise the amino acid residues that form the hypervariable loops. Hypervariable regions (HVRs) are also referred to as "complementarity determining regions" (CDRs), and these terms are used interchangeably herein with reference to the portions of the variable regions that form the antigen binding region. This particular region is described by Kabat et al., USDept. of Health and Human Services, Sequences of Proteins of Immunological Interest (1983) and Chothia et al., J Mol Biol 196:901-917 (1987), and the definitions include overlapping or subsets of amino acid residues when compared against each other. Nevertheless, application of either definition to refer to the CDR of an antibody or its variants is intended to be within the scope of the term as defined and used herein. The exact number of residues that encompass a particular CDR will vary depending on the sequence and size of the CDR. Those skilled in the art can routinely determine which residues comprise a particular CDR given the variable region amino acid sequence of an antibody.

[0094] The amino acid sequence boundaries of the CDRs can be determined by one of skill in the art using any of a number of known numbering schemes, including those described by Kabat et al. (supra) (the "Kabat" numbering scheme), Al-Lazikani et al., 1997, J. Mol. Biol., 273:927-948 (the "Chothia" numbering scheme), MacCallum et al., 1996, J. Mol. Biol. 262:732-745 (the "Contact" numbering scheme), Lefranc et al., Dev. Comp. Immunol., 2003, 27:55-77 (the "IMGT" numbering scheme), and Honegge and Pluckthun, J. Mol. Biol., 2001, 309:657-70 (the "AHo" numbering scheme), each of which is incorporated by reference in its entirety.

[0095] Table A provides the positions of CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3 as specified by the Kabat and Chothia schemes. For CDR-H1, residue numbering is provided using both the Kabat and Chothia numbering schemes.

[0096] CDRs may be assigned using antibody numbering software such as Abnum, for example, available at www.bioinf.org.uk / abs / abnum / and described in Abhinandan and Martin, Immunology, 2008, 45:3832-3839, incorporated by reference in its entirety.

[0097] [Table A]

[0098] The "EU numbering scheme" is generally used when referring to residues in antibody heavy chain constant regions (e.g., as reported in Kabat et al., supra). Unless otherwise stated, the EU numbering scheme is used to refer to residues in antibody heavy chain constant regions described herein.

[0099] As used herein, the term "single chain" refers to a molecule comprising amino acid monomers linearly linked by peptide bonds. In certain such embodiments, the C-terminus of the Fab light chain is connected to the N-terminus of the Fab heavy chain in a single chain Fab molecule. As described in more detail herein, an scFv has a variable domain of a light chain (VL) connected from its C-terminus to its N-terminus of the variable domain of a heavy chain (VH) by a polypeptide chain. Alternatively, an scFv comprises a polypeptide chain, in which the C-terminus of the VH is connected to the N-terminus of the VL by a polypeptide chain.

[0100] The "Fab fragment" (also called fragment antigen binding) contains the constant domain of the light chain (CL) and the first constant domain of the heavy chain (CH1) together with the variable domains VL and VH on the light and heavy chains, respectively. The variable domains contain the complementarity determining loops (CDRs, also called hypervariable regions) involved in antigen binding. Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region.

[0101] "F(ab') 2 The F(ab') fragment contains two Fab' fragments connected near the hinge region by disulfide bonds. 2 Fragments can be produced, for example, by recombinant methods or by pepsin digestion of intact antibodies. F(ab') fragments can be dissociated, for example, by treatment with β-mercaptoethanol.

[0102] An "Fv" fragment comprises a non-covalently associated dimer of one heavy- and one light-chain variable domain.

[0103] A "single-chain Fv" or "scFv" comprises the VH and VL domains of an antibody, wherein these domains are present in a single polypeptide chain. In one embodiment, the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains that enables the scFv to form the desired structure for antigen binding. For a review of scFvs, see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994). HER2 antibody scFv fragments are described in WO93 / 16185, U.S. Patent No. 5,571,894, and U.S. Patent No. 5,587,458.

[0104] An "scFv-Fc" fragment comprises an scFv connected to an Fc domain. For example, the Fc domain may be connected to the C-terminus of the scFv. The Fc domain determines the orientation of the variable domains within the scFv (i.e., H -V L or V L -V H ) depending on V H or V L Any suitable Fc domain known in the art or described herein may be used. In some cases, the Fc domain comprises an IgG4 Fc domain.

[0105] The term "single domain antibody" or "sdAb" refers to a molecule in which one variable domain of an antibody specifically binds to an antigen without the presence of the other variable domain. Single domain antibodies, and fragments thereof, are described in Arabi Ghahroudi et al., FEBS Letters, 1998, 414:521-526 and Muyldermans et al., Trends in Biochem. Sci., 2001, 26:230-245, each of which is incorporated by reference in its entirety. Single domain antibodies are also known as sdAbs or nanobodies. Sdabs are fairly stable and amenable to expression as fusion partners with the Fc chain of an antibody (Harmsen MM, De Haard HJ (2007). "Properties, production, and applications of camelid single-domain antibody fragments". Appl. Microbiol Biotechnol. 77(1):13-22).

[0106] The terms "full length antibody," "intact antibody," and "whole antibody" are used interchangeably herein and refer to an antibody having a structure substantially similar to a naturally occurring antibody structure and having a heavy chain, including an Fc region. For example, when used to refer to an IgG molecule, a "full length antibody" is an antibody that contains two heavy chains and two light chains.

[0107] The term "epitope" refers to a portion of an antigen that specifically binds to an antibody. Epitopes often consist of surface-accessible amino acid residues and / or sugar side chains and may have specific three-dimensional structural and charge characteristics. Conformational and non-conformational epitopes are distinguished in that the binding to the former, but not the latter, may be lost in the presence of denaturing solvents. Epitopes may include amino acid residues that are directly involved in binding and other amino acid residues that are not directly involved in binding. The epitope to which an antibody binds can be determined using known techniques for epitope determination, such as, for example, testing antibody binding to TREM2 variants with different point mutations or testing antibody binding to chimeric TREM2 variants.

[0108] A "multispecific antibody" is an antibody that comprises two or more different antigen-binding domains that collectively specifically bind to two or more different epitopes. The two or more different epitopes may be epitopes on the same antigen (e.g., a single TREM2 molecule expressed by a cell) or may be epitopes on different antigens (e.g., different TREM2 molecules, or a TREM2 molecule and a non-TREM2 molecule, expressed by the same cell). In some embodiments, a multispecific antibody binds to two different epitopes (i.e., a "bispecific antibody"). In some embodiments, a multispecific antibody binds to three different epitopes (i.e., a "trispecific antibody").

[0109] A "monospecific antibody" is an antibody that contains one or more binding sites that specifically bind to a single epitope. An example of a monospecific antibody is a naturally occurring IgG molecule that is bivalent (i.e., has two antigen-binding domains) but recognizes the same epitope at each of the two antigen-binding domains. The binding specificity may be present in any suitable valency.

[0110] The term "monoclonal antibody" refers to an antibody from a population of substantially homogeneous antibodies. A population of substantially homogeneous antibodies contains antibodies that are substantially similar and bind to the same epitope(s), except for variants that may normally arise during the production of monoclonal antibodies. Such variants are generally present only in minor amounts. Monoclonal antibodies are typically obtained by a process that includes selecting a single antibody from a plurality of antibodies. For example, the selection process can be the selection of a unique clone from a plurality of clones, such as a pool of hybridoma clones, phage clones, yeast clones, bacterial clones, or other recombinant DNA clones. The selected antibody can be further modified, for example, to improve affinity for a target ("affinity maturation"), to humanize the antibody, to improve its production in cell culture, and / or to reduce its immunogenicity in a subject.

[0111] "Effector function" refers to the biological activity mediated by the Fc region of an antibody, which activity may vary depending on the antibody isotype. Examples of antibody effector functions include C1q binding to activate complement-dependent cytotoxicity (CDC), Fc receptor binding to activate antibody-dependent cell-mediated cytotoxicity (ADCC), and antibody-mediated cellular phagocytosis (ADCP), receptor ligand blockade, or antagonism.

[0112] Anti-TREM2 antibodies may include those described herein, such as the clones shown in the tables. In some embodiments, the antibody comprises an alternative scaffold. In some embodiments, the antibody consists of an alternative scaffold. In some embodiments, the antibody consists essentially of an alternative scaffold. In some embodiments, the antibody comprises an antibody fragment. In some embodiments, the antibody consists of an antibody fragment. In some embodiments, the antibody consists essentially of an antibody fragment. A "TREM2 antibody," "anti-TREM2 antibody," or "TREM2-specific antibody," as provided herein, is an antibody that specifically binds to the antigen TREM2. In some embodiments, the antibody binds to the extracellular domain of TREM2. In certain embodiments, the TREM2 antibodies provided herein bind to an epitope of TREM2 that is conserved between or across TREM2 proteins from different species.

[0113] The term "chimeric antibody" refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, while the remainder of the heavy and / or light chain is derived from a different source or species.

[0114] "Humanized" forms of non-human antibodies are chimeric antibodies that contain minimal sequence derived from the non-human antibody. Humanized antibodies are generally human antibodies (recipient antibodies) in which residues from one or more CDRs are replaced by residues from one or more CDRs of a non-human antibody (donor antibody). The donor antibody can be any suitable non-human antibody, e.g., mouse, rat, rabbit, chicken, or non-human primate antibody, with the desired specificity, affinity, or biological effect. Humanized antibodies are less likely to induce an immune response and / or induce a less severe immune response when administered to a human subject, compared to non-human species antibodies. In some cases, selected framework region residues of the recipient antibody are replaced by the corresponding framework region residues from the donor antibody. Humanized antibodies may also contain residues that are not found in either the recipient antibody or the donor antibody. Such modifications may be made to further fine-tune antibody function. Examples of methods for making humanized antibodies can be found in U.S. Patent Nos. 6,054,297, 5,886,152, and 5,877,293, each of which is incorporated by reference in its entirety. For further details, see Jones et al., Nature, 1986, 321:522-525, Riechmann et al., Nature, 1988, 332:323-329, and Presta, Curr. Op. Struct. Biol., 1992, 2:593-596, each of which is incorporated by reference in its entirety.

[0115] In one embodiment, the constant domain(s) from a human antibody are fused to the variable domain(s) of a non-human species. In another embodiment, one or more amino acid residues within one or more CDR sequences of the non-human antibody are altered to reduce the immunogenic potential of the non-human antibody when administered to a human subject, either the altered amino acid residues are not important for immunospecific binding of the antibody to its antigen, or the changes to the amino acid sequence made are conservative changes such that binding of the humanized antibody to the antigen is not significantly worse than binding of the non-human antibody to the antigen.

[0116] A "human antibody" is one having an amino acid sequence that corresponds to that of an antibody produced by a human or human cell, or an amino acid sequence derived from a non-human source that utilizes a human antibody repertoire or human antibody coding sequences (e.g., obtained from a human source or designed de novo). Human antibodies specifically exclude humanized antibodies. In one embodiment, all of the variable and constant domains are derived from human immunoglobulin sequences (fully human antibodies). These antibodies can be prepared in a variety of ways, including by immunization with the antigen of interest of mice that are genetically engineered to express antibodies derived from genes encoding human heavy and / or light chains.

[0117] In some embodiments, the antibodies provided herein comprise an antibody fragment. In some embodiments, the antibodies provided herein consist of an antibody fragment. In some embodiments, the antibodies provided herein consist essentially of an antibody fragment. In some embodiments, the antibody fragment is an Fv fragment. In some embodiments, the antibody fragment is a Fab fragment. In some embodiments, the antibody fragment is an F(ab') 2 In some embodiments, the antibody fragment is a Fab' fragment. In some embodiments, the antibody fragment is an scFv (sFv) fragment. In some embodiments, the antibody fragment is an scFv-Fc fragment. In some embodiments, the antibody fragment is a fragment of a single domain antibody.

[0118] TREM2 antibody sequence V H domain In some embodiments, the antibodies provided herein comprise a V H In some embodiments, the antibodies provided herein comprise the V H In some embodiments, the antibodies provided herein comprise the V H In some embodiments, the antibodies provided herein comprise the V HIn some embodiments, the antibodies provided herein comprise the V H Contains arrays.

[0119] In some embodiments, the antibodies provided herein comprise an exemplary VVLK antibody as provided in SEQ ID NOs: 1, 3, 5, and 7. H V having at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to the sequence H In some embodiments, the antibodies provided herein include those provided in SEQ ID NOs: 1, 3, 5, and 7, with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acid substitutions. H The antibody may be a nucleotide sequence, such as nucleotide sequence 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 109, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119,

[0120] V L domain In some embodiments, the antibodies provided herein comprise a V L In some embodiments, the antibodies provided herein comprise the V L In some embodiments, the antibodies provided herein comprise the V L In some embodiments, the antibodies provided herein comprise the V L In some embodiments, the antibodies provided herein comprise the V L Contains arrays.

[0121] In some embodiments, the antibodies provided herein comprise an exemplary VVLK antibody as provided in SEQ ID NOs: 2, 4, 6, and 8. L V having at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to the sequence L In some embodiments, the antibodies provided herein include those provided in SEQ ID NOs: 2, 4, 6, and 8, which have up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acid substitutions. L The antibody may be a nucleotide sequence, such as nucleotide sequence 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 109, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119,

[0122] V H -V L Combination of In some embodiments, the antibodies provided herein comprise a V H and V selected from SEQ ID NOs: 2, 4, 6, and 8. L and an array.

[0123] In some embodiments, the antibodies provided herein comprise a polypeptide comprising the V H Sequence and V of SEQ ID NO:2 L In some embodiments, the antibodies provided herein comprise the V H Sequence and V of SEQ ID NO:4 LIn some embodiments, the antibodies provided herein comprise the V H Sequence and V of SEQ ID NO:6 L In some embodiments, the antibodies provided herein comprise the V H Sequence and V of SEQ ID NO:8 L In certain embodiments, any of SEQ ID NOs: 1, 3, 5, and 7 can be combined with any of SEQ ID NOs: 2, 4, 6, and 8. For example, SEQ ID NO: 1 can be combined with any of SEQ ID NOs: 2, 4, 6, or 8. As another example, SEQ ID NO: 2 can be combined with any of SEQ ID NOs: 1, 3, 5, or 7.

[0124] In some embodiments, the antibodies provided herein comprise an exemplary VVLK antibody as provided in SEQ ID NOs: 1, 3, 5, and 7. H V having at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to the sequence H and VL sequences having at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to the illustrative VL sequences provided in SEQ ID NOs: 2, 4, 6, and 8. LIn some embodiments, the antibodies provided herein comprise a VH sequence provided in SEQ ID NOs: 1, 3, 5, and 7, with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acid substitutions, and a VL sequence provided in SEQ ID NOs: 2, 4, 6, and 8, with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as "variants." In some embodiments, such variants are derived from the sequences provided herein, e.g., by affinity maturation, site-directed mutagenesis, random mutagenesis, or any other method known in the art or described herein, In some embodiments, such variants are not derived from the sequences provided herein, and may be isolated de novo, e.g., according to the methods provided herein for obtaining antibodies.

[0125] CDR In some embodiments, the antibodies provided herein comprise a V H In some embodiments, the antibodies provided herein comprise one to three CDRs of a V domain selected from SEQ ID NOs: 1, 3, 5, and 7. H In some embodiments, the antibodies provided herein comprise three CDRs of a VH domain selected from SEQ ID NOs: 1, 3, 5, and 7. In some aspects, the CDRs are exemplary CDRs. In some aspects, the CDRs are Kabat CDRs. In some aspects, the CDRs are Chothia CDRs. In some aspects, the CDRs are AbM CDRs. In some aspects, the CDRs are Contact CDRs. In some aspects, the CDRs are IMGT CDRs.

[0126] The CDRs of VH of SEQ ID NO:1 and VL of SEQ ID NO:2 as defined using Kabat, Chothia, AbM, Contact, and IMGT are shown below in Table B. Exemplary CDRs of VH are provided as SEQ ID NOs:9, 10, and 11. Exemplary CDRs of VL are provided as SEQ ID NOs:12, 13, and 14.

[0127] [Table B]

[0128] In some embodiments, the CDRs are CDRs having at least about 50%, 75%, 80%, 85%, 90%, or 95% identity with CDR-H1, CDR-H2, or CDR-H3 of SEQ ID NOs: 1, 3, 5, and 7. In some embodiments, the CDR-H1 is the CDR-H1 of a VH domain selected from SEQ ID NOs: 1, 3, 5, and 7, with up to 1, 2, 3, 4, or 5 amino acid substitutions. In some embodiments, the CDR-H2 is the CDR-H2 of a VH domain selected from SEQ ID NOs: 1, 3, 5, and 7, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some embodiments, the CDR-H3 is the CDR-H3 of a VH domain selected from SEQ ID NOs: 1, 3, 5, and 7, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as "variants." In some embodiments, such variants are derived from the sequences provided herein, for example, by affinity maturation, site-directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from the sequences provided herein, and may be isolated de novo, for example, according to the methods provided herein for obtaining antibodies.

[0129] In some embodiments, the antibodies provided herein comprise one to three CDRs of a VL domain selected from SEQ ID NOs: 2, 4, 6, and 8. In some embodiments, the antibodies provided herein comprise two to three CDRs of a VL domain selected from SEQ ID NOs: 2, 4, 6, and 8. In some embodiments, the antibodies provided herein comprise three CDRs of a VL domain selected from SEQ ID NOs: 2, 4, 6, and 8. In some aspects, the CDRs are exemplary CDRs. In some aspects, the CDRs are Kabat CDRs. In some aspects, the CDRs are Chothia CDRs. In some aspects, the CDRs are AbM CDRs. In some aspects, the CDRs are Contact CDRs. In some aspects, the CDRs are IMGT CDRs.

[0130] In some embodiments, the CDRs are CDRs having at least about 50%, 75%, 80%, 85%, 90%, or 95% identity to CDR-L1, CDR-L2, or CDR-L3 of SEQ ID NOs: 2, 4, 6, and 8. In some embodiments, the CDR-L1 is the CDR-L1 of a VL domain selected from SEQ ID NOs: 2, 4, 6, and 8, with up to 1, 2, 3, 4, or 5 amino acid substitutions. In some embodiments, the CDR-L2 is the CDR-L2 of a VL domain selected from SEQ ID NOs: 2, 4, 6, and 8, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some embodiments, the CDR-L3 is the CDR-L3 of a VL domain selected from SEQ ID NOs: 2, 4, 6, and 8, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as "variants." In some embodiments, such variants are derived from the sequences provided herein, for example, by affinity maturation, site-directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from the sequences provided herein, and may be isolated de novo, for example, according to the methods provided herein for obtaining antibodies.

[0131] In some embodiments, the antibodies provided herein comprise one to three CDRs of a VH domain selected from SEQ ID NOs: 1, 3, 5, and 7, and one to three CDRs of a VL domain selected from SEQ ID NOs: 2, 4, 6, and 8. In some embodiments, the antibodies provided herein comprise two to three CDRs of a VH domain selected from SEQ ID NOs: 1, 3, 5, and 7, and two to three CDRs of a VL domain selected from SEQ ID NOs: 2, 4, 6, and 8. In some embodiments, the antibodies provided herein comprise three CDRs of a VH domain selected from SEQ ID NOs: 1, 3, 5, and 7, and three CDRs of a VL domain selected from SEQ ID NOs: 2, 4, 6, and 8. In some aspects, the CDRs are exemplary CDRs. In some aspects, the CDRs are Kabat CDRs. In some aspects, the CDRs are Chothia CDRs. In some aspects, the CDRs are AbM CDRs. In some aspects, the CDRs are Contact CDRs. In some embodiments, the CDRs are IMGT CDRs.

[0132] In some embodiments, the antibodies provided herein comprise a CDR-H3 selected from SEQ ID NO: 11, 39, 51, or 52. In some aspects, the CDR-H3 has at least about 50%, 75%, 80%, 85%, 90%, or 95% identity to the CDR-H3 of SEQ ID NO: 11, 39, 51, or 52. In some embodiments, the CDR-H3 is a CDR-H3 selected from SEQ ID NO: 11, 39, 51, or 52 with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as "variants." In some embodiments, such variants are derived from the sequences provided herein, for example, by affinity maturation, site-directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from the sequences provided herein and may be isolated de novo, e.g., according to the methods provided herein for obtaining antibodies.

[0133] In some embodiments, the antibodies provided herein comprise a CDR-H2 of SEQ ID NO: 10, 47, 48, 49, or 50. In some aspects, the CDR-H2 has at least about 50%, 75%, 80%, 85%, 90%, or 95% identity to the CDR-H2 of SEQ ID NO: 10, 47, 48, 49, or 50. In some embodiments, the CDR-H2 is a CDR-H2 of SEQ ID NO: 10, 47, 48, 49, or 50 with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as "variants." In some embodiments, such variants are derived from the sequences provided herein, for example, by affinity maturation, site-directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from the sequences provided herein and may be isolated de novo, e.g., according to the methods provided herein for obtaining antibodies.

[0134] In some embodiments, the antibodies provided herein comprise a CDR-H1 of SEQ ID NO: 9, 37, 43, 44, 45, or 46. In some aspects, the CDR-H1 has at least about 50%, 75%, 80%, 85%, 90%, or 95% identity with the CDR-H1 of SEQ ID NO: 9, 37, 43, 44, 45, or 46. In some embodiments, the CDR-H1 is a CDR-H1 of SEQ ID NO: 9, 37, 43, 44, 45, or 46 with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as "variants." In some embodiments, such variants are derived from the sequences provided herein, for example, by affinity maturation, site-directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from the sequences provided herein and may be isolated de novo, e.g., according to the methods provided herein for obtaining antibodies.

[0135] In some embodiments, the antibodies provided herein comprise a CDR-H3 of SEQ ID NO: 11, 39, 51, or 52, and a CDR-H2 of SEQ ID NO: 10. In some embodiments, the antibodies provided herein comprise a CDR-H3 of SEQ ID NO: 11, 39, 51, or 52, a CDR-H2 of SEQ ID NO: 10, 47, 48, 49, or 50, and a CDR-H1 of SEQ ID NO: 9, 37, 43, 44, 45, or 46. In some embodiments, CDR-H3 has at least about 50%, 75%, 80%, 85%, 90% or 95% identity to CDR-H3 of SEQ ID NO: 11, 39, 51 or 52, CDR-H2 has at least about 50%, 75%, 80%, 85%, 90% or 95% identity to CDR-H2 of SEQ ID NO: 10, 47, 48, 49 or 50, and CDR-H1 has at least about 50%, 75%, 80%, 85%, 90% or 95% identity to CDR-H1 of SEQ ID NO: 9, 37, 43, 44, 45 or 46. In some embodiments, the CDR-H3 is CDR-H3 of SEQ ID NO: 11, 39, 51, or 52 with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions, the CDR-H2 is CDR-H2 of SEQ ID NO: 10, 47, 48, 49, or 50 with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions, and the CDR-H1 is CDR-H1 of SEQ ID NO: 9, 37, 43, 44, 45, or 46 with up to 1, 2, 3, 4, or 5 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as "variants". In some embodiments, such variants are derived from the sequences provided herein, for example, by affinity maturation, site-directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from the sequences provided herein and may be isolated de novo, e.g., according to the methods provided herein for obtaining antibodies.

[0136] In some embodiments, the antibodies provided herein comprise a CDR-L3 of SEQ ID NO: 14, 42, or 57. In some aspects, the CDR-L3 has at least about 50%, 75%, 80%, 85%, 90%, or 95% identity with the CDR-L3 of SEQ ID NO: 14, 42, or 57. In some embodiments, the CDR-L3 is a CDR-L3 of SEQ ID NO: 14, 42, or 57 with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as "variants." In some embodiments, such variants are derived from the sequences provided herein, for example, by affinity maturation, site-directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from the sequences provided herein and may be isolated de novo, e.g., according to the methods provided herein for obtaining antibodies.

[0137] In some embodiments, the antibodies provided herein comprise a CDR-L2 of SEQ ID NO: 13 or 55. In some aspects, the CDR-L2 has at least about 50%, 75%, 80%, 85%, 90%, or 95% identity with the CDR-L2 of SEQ ID NO: 13 or 55. In some embodiments, the CDR-L2 is a CDR-L2 of SEQ ID NO: 13 or 55 with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as "variants." In some embodiments, such variants are derived from the sequences provided herein, for example, by affinity maturation, site-directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from the sequences provided herein, and may be isolated de novo, for example, according to the methods provided herein for obtaining antibodies.

[0138] In some embodiments, the antibodies provided herein comprise a CDR-L1 of SEQ ID NO: 12. In some aspects, the CDR-L1 has at least about 50%, 75%, 80%, 85%, 90%, or 95% identity with the CDR-L1 of SEQ ID NO: 12, 40, 53, or 54. In some embodiments, the CDR-L1 is a CDR-L1 of SEQ ID NO: 12, 40, 53, or 54 with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as "variants." In some embodiments, such variants are derived from the sequences provided herein, for example, by affinity maturation, site-directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from the sequences provided herein and may be isolated de novo, e.g., according to the methods provided herein for obtaining antibodies.

[0139] In some embodiments, the antibodies provided herein comprise a CDR-L3 of SEQ ID NO: 14, 42, or 57, and a CDR-L2 of SEQ ID NO: 13 or 55. In some embodiments, the antibodies provided herein comprise a CDR-L3 of SEQ ID NO: 14, 42, or 57, a CDR-L2 of SEQ ID NO: 13 or 55, and a CDR-L1 of SEQ ID NO: 12, 40, 53, or 54. In some embodiments, CDR-L3 has at least about 50%, 75%, 80%, 85%, 90% or 95% identity to CDR-L3 of SEQ ID NO: 14, 42 or 57, CDR-L2 has at least about 50%, 75%, 80%, 85%, 90% or 95% identity to CDR-L2 of SEQ ID NO: 13 or 55, and CDR-L1 has at least about 50%, 75%, 80%, 85%, 90% or 95% identity to CDR-L1 of SEQ ID NO: 12, 40, 53 or 54. In some embodiments, the CDR-L3 is CDR-L3 of SEQ ID NO: 14, 42, or 57 with up to 1, 2, 3, 4, or 5 amino acid substitutions, the CDR-L2 is CDR-L2 of SEQ ID NO: 13 or 55 with up to 1, 2, 3, or 4 amino acid substitutions, and the CDR-L1 is CDR-L1 of SEQ ID NO: 12, 40, 53, or 54 with up to 1, 2, 3, 4, 5, or 6 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as "variants". In some embodiments, such variants are derived from the sequences provided herein, for example, by affinity maturation, site-directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from the sequences provided herein, and may be isolated de novo, for example, according to the methods provided herein for obtaining antibodies.

[0140] In some embodiments, the antibodies provided herein comprise a CDR-H3 of SEQ ID NO: 11, 39, 51, or 52; a CDR-H2 of SEQ ID NO: 10, 47, 48, 49, or 50; a CDR-H1 of SEQ ID NO: 9, 37, 43, 44, 45, or 46; a CDR-L3 of SEQ ID NO: 14, 42, or 57; a CDR-L2 of SEQ ID NO: 13 or 55; and a CDR-L1 of SEQ ID NO: 12, 40, 53, or 54. In some embodiments, CDR-H3 has at least about 50%, 75%, 80%, 85%, 90%, or 95% identity to CDR-H3 of SEQ ID NO: 11, 39, 51, or 52, CDR-H2 has at least about 50%, 75%, 80%, 85%, 90%, or 95% identity to CDR-H2 of SEQ ID NO: 10, 47, 48, 49, or 50, and CDR-H1 has at least about 50%, 75%, 80%, 85%, 90% identity to CDR-H1 of SEQ ID NO: 9, 37, 43, 44, 45, or 46. , or 95% identity to CDR-L3 of SEQ ID NO: 14, 42, or 57; CDR-L2 has at least about 50%, 75%, 80%, 85%, 90% or 95% identity to CDR-L2 of SEQ ID NO: 13 or 55; and CDR-L1 has at least about 50%, 75%, 80%, 85%, 90% or 95% identity to CDR-L1 of SEQ ID NO: 12, 40, 53, or 54.In some embodiments, the CDR-H3 is CDR-H3 of SEQ ID NO: 11, 39, 51, or 52 with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions, the CDR-H2 is CDR-H2 of SEQ ID NO: 10, 47, 48, 49, or 50 with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions, and the CDR-H1 is CDR-H2 of SEQ ID NO: 9, 37, 43, 44, 45, 46, 47, 48, 49, or 50 with up to 1, 2, 3, 4, or 5 amino acid substitutions. The CDR-H1 is SEQ ID NO: 14, 42, or 57 with up to 1, 2, 3, 4, or 5 amino acid substitutions, the CDR-L2 is SEQ ID NO: 13 or 55 with up to 1, 2, 3, or 4 amino acid substitutions, and the CDR-L1 is SEQ ID NO: 12, 40, 53, or 54 with up to 1, 2, 3, 4, 5, or 6 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as "variants". In some embodiments, such variants are derived from the sequences provided herein, for example, by affinity maturation, site-directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from the sequences provided herein and may be isolated de novo, e.g., according to the methods provided herein for obtaining antibodies.

[0141] In some embodiments, the antibodies provided herein comprise a CDR-H1 of SEQ ID NO: 9, a CDR-H2 of SEQ ID NO: 10, a CDR-H3 of SEQ ID NO: 11, a CDR-L1 of SEQ ID NO: 12, a CDR-L2 of SEQ ID NO: 13, and a CDR-L1 of SEQ ID NO: 14.

[0142] Fc area The term "Fc domain" or "Fc region" herein is used to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. This term includes native sequence Fc regions and variant Fc regions. Unless otherwise specified herein, the numbering of amino acid residues in an Fc region or constant region is according to the EU numbering system (also called the EU index) as described in Kabat et al, Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991. As used herein, the "Fc polypeptide" of a dimeric Fc refers to one of the two polypeptides that form the dimeric Fc domain, i.e., a polypeptide that contains the C-terminal constant region of an immunoglobulin heavy chain that is capable of stable self-association. For example, the Fc polypeptide of a dimeric IgG Fc contains IgG CH2 and IgG CH3 constant domain sequences. The Fc may be of the classes IgA, IgD, IgE, IgG, and IgM, some of which have subclasses (isotypes), e.g., IgG 1 , IgG 2 , IgG 3 , IgG 4 , IgA 1 , and IgA 2 It can be further divided into:

[0143] The terms "Fc receptor" and "FcR" are used to describe a receptor that binds to the Fc region of an antibody. For example, an FcR may be a native sequence human FcR. In general, an FcR is one that binds IgG antibodies (gamma receptors) and includes receptors of the FcγRI, FcγRII, and FcγRIII subclasses, including allelic variants and alternatively spliced ​​forms of these receptors. FcγRII receptors include FcγRIIA ("activating receptors") and FcγRIIB ("inhibiting receptors"), which have similar amino acid sequences that differ primarily in their cytoplasmic domains. Immunoglobulins of other isotypes can also bind to specific FcRs (see, e.g., Janeway et al., Immuno Biology: the immune system in health and disease, (Elsevier Science Ltd., NY) (4th ed., 1999)). The activating receptor FcγRIIA contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. Inhibitory receptor FcγRIIB contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) in its cytoplasmic domain (reviewed in Daeron, Annu. Rev. Immunol. 15:203-234 (1997)). FcRs are reviewed in Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991), Capel et al., Immunomethods 4:25-34 (1994), and de Haas et al., J. Lab. Clin. Med. 126:330-41 (1995). Other FcRs, including those identified in the future, are encompassed by the term "FcR" herein. The term also includes FcRn, the neonatal receptor responsible for transfer of maternal IgG to the fetus (Guyer et al., J. Immunol. 117:587 (1976), and Kim et al., J. Immunol. 24:249 (1994)).

[0144] In some embodiments, the antibody is an IgG1 antibody.

[0145] In some embodiments, the antibody is an IgG3 antibody.

[0146] In some embodiments, the antibody is an IgG2 antibody.

[0147] In some embodiments, the antibody is an IgG4 antibody.

[0148] Modifications in the CH2 domain can affect the binding of FcR to Fc. Several amino acid modifications in the Fc region are known in the art to selectively modify the affinity of Fc to different Fc gamma (Fcγ) receptors. In one embodiment, Fc comprises one or more modifications to promote selective binding to Fc-gamma receptors. In another embodiment, Fc comprises one or more modifications that reduce the binding affinity to Fc-gamma receptors.

[0149] Exemplary mutations that alter binding of FcR to Fc are listed below.

[0150] S298A / E333A / K334A, S298A / E333A / K334A / K326A (Lu Y, Vernes JM, Chiang N, et al. J Immunol Methods.2011 Feb 28;365(1-2):132-41).

[0151] F243L / R292P / Y300L / V305I / P396L, F243L / R292P / Y300L / L235V / P396L (Stavenhagen JB, Gorlatov S, Tuaillon N, et al. Cancer Res. 2007 Sep 15;67(18):8882-90, Nordstrom JL, Gorlatov S, Zhang W, et al.Breast Cancer Res.2011 Nov 30;13(6):R123).

[0152] F243L(Stewart R,Thom G,Levens M,et al.Protein Eng Des Sel.2011 Sep;24(9):671-8.), S298A / E333A / K334A(Shields RL,Namenuk AK,Hong K,et al.J Biol Chem.2001 Mar 2;276(9):6591-604).

[0153] S239D / I332E / A330L, S239D / I332E (Lazar GA, Dang W, Karki S, et al. Proc Natl Acad Sci US A. 2006 Mar 14;103(11):4005-10).

[0154] S239D / S267E, S267E / L328F (Chu SY, Vostiar I, Karki S, et al. Mol Immunol. 2008 Sep;45(15):3926-33).

[0155] S239D / D265S / S298A / I332E, S239E / S298A / K326A / A327H, G237F / S298A / A330L / I332E, S239D / I332E / S298A, S239D / K326E / A330L / I332E / S298A, G236A / S239D / D270L / I332E, S239E / S267E / H268D, L234F / S267E / N325L, G237F / V266L / S267D, and other mutations listed in WO2011 / 120134 and WO2011 / 120135, which are incorporated by reference herein. Therapeutic Antibody Engineering (by William R. Strohl and Lila M. Strohl, Woodhead Publishing series in Biomedicine No 11, ISBN 1 907568 37 9, Oct 2012) lists the mutations on page 283.

[0156] In some embodiments, the antibodies described herein include modifications to improve their ability to mediate effector functions. Such modifications are known in the art and include defucosylation, or engineering the affinity of Fc for activating receptors (mainly FCGR3a for ADCC, and C1q for CDC). Table C below summarizes the various designs reported in the literature for effector function engineering.

[0157] In certain embodiments, the antibodies provided herein comprise an Fc region with one or more amino acid substitutions that improve ADCC, e.g., substitutions at one or more of Fc region positions 298, 333, and 334. In some embodiments, the antibodies provided herein comprise an Fc region with one or more amino acid substitutions at positions 239, 332, and 330, as described in Lazar et al., Proc. Natl. Acad. Sci. USA, 2006, 103:4005-4010, incorporated by reference in its entirety.

[0158] In some embodiments, the antibodies provided herein contain one or more modifications that improve or decrease C1q binding and / or CDC, see U.S. Patent No. 6,194,551, WO 99 / 51642, and Idusogie et al., J. Immunol., 2000, 164:4178-4184, each of which is incorporated by reference in its entirety.

[0159] Thus, in one embodiment, the antibodies described herein may comprise a dimeric Fc that contains one or more amino acid modifications as described in Table B that confer improved effector function. In another embodiment, the antibodies may be defucosylated to improve effector function.

[0160] [Table C]

[0161] Fc modifications that reduce FcγR and / or complement binding and / or effector function are known in the art. Antibodies containing such modifications are referred to as "Fc-silent" antibodies. Recent publications have described strategies that have been used to engineer antibodies with reduced or silenced effector activity (see Strohl, WR (2009), Curr Opin Biotech 20:685-691, and Strohl, WR and Strohl LM, "Antibody Fc engineering for optimal antibody performance" In Therapeutic Antibody Engineering, Cambridge: Woodhead Publishing (2012), pp225-249). These strategies include reducing effector function by modifying glycosylation, using an IgG2 / IgG4 scaffold, or introducing mutations in the hinge or CH2 regions of Fc. For example, U.S. Patent Publication No. 2011 / 0212087 (Strohl), International Patent Publication No. WO2006 / 105338 (Xencor), U.S. Patent Publication No. 2012 / 0225058 (Xencor), U.S. Patent Publication No. 2012 / 0251531 (Genentech), U.S. Patent Publication No. 2011 / 0059075 (Rockefeller University / MIT), and Strop et al ((2012) J. Mol. Biol. 420:204-219) describe specific modifications to reduce binding of FcγR or complement to Fc.

[0162] Specific non-limiting examples of known amino acid modifications to reduce FcγR or complement binding to Fc include those identified in Table D below.

[0163] [Table D]

[0164] Methods for producing antibodies with little or no fucose on the Fc glycosylation site (Asn 297 EU numbering) without altering the amino acid sequence are well known in the art. GlymaxX® technology (ProBioGen AG) is based on the introduction of a gene for an enzyme that redirects the cellular pathway of fucose biosynthesis into cells used for antibody production. This prevents the addition of the sugar "fucose" to the N-linked antibody carbohydrate moiety by the antibody-producing cells. (von Horsten et al. (2010) Glycobiology. 2010 Dec;20(12):1607-18.) Examples of cell lines capable of producing defucosylated antibodies include CHO-DG44 with stable expression of the bacterial oxidoreductase GDP-6-deoxy-D-lyxo-4-hexylose reductase (RMD) (see Henning von Horsten et al., Glycobiol 2010,20:1607-1618), or Lec13 CHO cells, which are deficient in protein fucosylation (see Ripka et al., each of which is incorporated by reference in its entirety). al., Arch. Biochem. Biophys., 1986, 249:533-545; U.S. Patent Publication No. 2003 / 0157108; WO2004 / 056312), as well as knockout cell lines such as alpha-1,6-fucosyltransferase gene or FUT8 knockout CHO cells (Yamane-Ohnuki et al., Biotech. Bioeng., 2004, 87:614-622; Kanda et al., Biotechnol. Bioeng., 2006, 94:680-688; and WO2003 / 085107, each of which is incorporated by reference in its entirety). Another approach to obtaining antibodies with reduced levels of fucosylation can be found in U.S. Pat. No. 8,409,572, which teaches selecting cell lines for antibody production for their ability to reduce the level of fucosylation on the antibody.

[0165] The antibody can be fully defucosylated (meaning that it contains no detectable fucose) or partially defucosylated, meaning that the isolated antibody contains less than 95%, less than 85%, less than 75%, less than 65%, less than 55%, less than 45%, less than 35%, less than 25%, less than 15%, or less than 5% of the amount of fucose typically detected for a similar antibody produced by a mammalian expression system.

[0166] In some embodiments, the antibodies provided herein comprise an IgG1 domain with reduced fucose content at position Asn297 compared to naturally occurring IgG1 domains. Such Fc domains are known to have improved ADCC. See Shields et al., J.Biol.Chem., 2002, 277:26733-26740, which is incorporated by reference in its entirety. In some embodiments, such antibodies do not contain any fucose at position Asn297. The amount of fucose can be determined using any suitable method, for example, as described in WO2008 / 077546, which is incorporated by reference in its entirety.

[0167] In some embodiments, the antibodies provided herein comprise a bisected oligosaccharide, e.g., a biantennary oligosaccharide attached to the Fc region of the antibody that is bisected by GlcNAc. Such antibody variants may have reduced fucosylation and / or improved ADCC function. Examples of such antibody variants are described, for example, in WO2003 / 011878, U.S. Patent No. 6,602,684, and U.S. Patent Publication No. 2005 / 0123546, each of which is incorporated by reference in its entirety.

[0168] Other illustrative glycosylation variants that can be incorporated into the antibodies provided herein are described, e.g., in U.S. Patent Publication Nos. 2003 / 0157108, 2004 / 0093621, 2003 / 0157108, 2003 / 0115614, 2002 / 0164328, 2004 / 0093621, 2004 / 0132140, 2004 / 01 10704, 2004 / 0110282, 2004 / 0109865, International Patent Publication Nos. 2000 / 61739, 2001 / 29246, 2003 / 085119, 2003 / 084570, 2005 / 035586, 2005 / 035778, 2005 / 053742, 2002 / 031140, Okazaki et al., J. Mol. Biol., 2004, 336:1239-1249, and Yamane-Ohnuki et al., Biotech. Bioeng., 2004, 87:614-622, each of which is incorporated by reference in its entirety.

[0169] In some embodiments, the antibodies provided herein comprise an Fc region having at least one galactose residue in the oligosaccharide attached to the Fc region. Such antibody variants may have improved CDC function. Examples of such antibody variants are described, for example, in WO1997 / 30087, WO1998 / 58964, and WO1999 / 22764, each of which is incorporated by reference in its entirety.

[0170] Examples of cell lines capable of producing defucosylated antibodies include CHO-DG44 with stable expression of the bacterial oxidoreductase GDP-6-deoxy-D-lyxo-4-hexylose reductase (RMD) (see Henning von Horsten et al., Glycobiol 2010, 20:1607-1618), or Lec13 CHO cells that are deficient in protein fucosylation (see Ripka et al., Arch. Biochem. Biophys., 1986, 249:533-545; U.S. Patent Publication No. 2003 / 0157108; WO 2004 / 056312, each of which is incorporated by reference in its entirety), as well as knockout cell lines such as alpha-1,6-fucosyltransferase gene or FUT8 knockout CHO cells (Yamane-Ohnuki et al., J. Med. Soc. 2004, 11:111-112, each of which is incorporated by reference in its entirety). al., Biotech. Bioeng., 2004, 87:614-622; Kanda et al., Biotechnol. Bioeng., 2006, 94:680-688; and WO2003 / 085107 (each of which is incorporated by reference in its entirety).

[0171] In some embodiments, the antibody has antibody-dependent cellular phagocytosis (ADCP) activity. ADCP can occur when an antibody binds to an antigen on the surface of a target cell. Phagocytes, including monocytes and macrophages, which have Fc receptors on their cell surface, recognize and bind the Fc region of an antibody bound to a target cell. Upon binding of the Fc receptor to the antibody-bound target cell, phagocytosis of the target cell can be initiated. ADCP can be considered a form of ADCC.

[0172] In some embodiments, the antibody is capable of forming an immune complex, for example, the immune complex may be a cell coated with the antibody.

[0173] In some embodiments, the antibody is a monoclonal antibody.

[0174] In some embodiments, the antibody is a polyclonal antibody.

[0175] In some embodiments, the antibody is produced by a hybridoma, hi other embodiments, the antibody is produced by a recombinant cell that has been engineered to express the desired variable and constant domains.

[0176] In some embodiments, the antibody may be a single chain antibody or other antibody derivative or variant thereof that retains the antigen specificity and lower hinge region.

[0177] In some embodiments, the antibody may be a polyfunctional antibody, a recombinant antibody, a human antibody, a humanized antibody, a fragment or a variant thereof. In certain embodiments, the antibody fragment or derivative thereof is selected from a Fab fragment, a Fab'2 fragment, a CDR, and a ScFv.

[0178] In some embodiments, the antibody is specific for a surface antigen, such as the TREM2 protein. In some embodiments, the therapeutic antibody is specific for an antigen (e.g., a molecule specifically expressed by an antigen-bearing target cell). In certain embodiments, the therapeutic antibody may have a human or non-human primate IgG1 or IgG3 Fc portion.

[0179] join With respect to antibody binding to a target molecule, the terms "binding," "specific binding," "specifically binds to," "specifically binds to," "selectively binds to," and "selective for" to a particular antigen (e.g., a polypeptide target) or epitope on a particular antigen refer to binding that is measurably different from nonspecific or nonselective interactions (e.g., with a non-target molecule). Specific binding can be measured, for example, by measuring binding to a target molecule and comparing it to binding to a non-target molecule. Specific binding can also be determined by competition with a control molecule that mimics the epitope recognized on the target molecule. Specific binding is then indicated if binding of the antibody to the target molecule is competitively inhibited by the control molecule.

[0180] "Affinity" refers to the total strength of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen or epitope). Unless otherwise indicated, as used herein, "affinity" refers to the intrinsic binding affinity that reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen or epitope). The affinity of a molecule X for its partner Y is determined by the dissociation equilibrium constant (K D The kinetic components that contribute to the dissociation equilibrium constant are described in more detail below. Affinity can be measured by common methods known in the art, including those described herein, such as surface plasmon resonance (SPR) technology (e.g., BIACORE®) or biolayer interferometry (e.g., FORTEBIO®).

[0181] "k d " (sec -1 The term k ) as used herein refers to the dissociation rate constant of a particular antibody-antigen interaction. This value is known as k off Also called the value.

[0182] "k a " " -1 ×sec -1The term k ) as used herein refers to the association rate constant of a particular antibody-antigen interaction. This value is known as k on Also called the value.

[0183] "K D The term "(M)" as used herein refers to the dissociation equilibrium constant of a particular antibody-antigen interaction. D =k d / k a In some embodiments, the affinity of an antibody is determined by the K D For clarity, as is known in the art, the smaller K D A larger K value indicates a greater affinity interaction. D Values ​​indicate smaller affinity interactions.

[0184] "K A " " -1 The term K ) as used herein refers to the association equilibrium constant of a particular antibody-antigen interaction. A =k a / k d .

[0185] The term "competes with" or "cross-competes with" as used herein with respect to two or more antibodies indicates that two or more antibodies compete for binding to an antigen (e.g., TREM2). In one exemplary assay, TREM2 is coated on a surface and contacted with a first TREM2 antibody, followed by the addition of a second TREM2 antibody. In another exemplary assay, a first TREM2 antibody is coated on a surface and contacted with TREM2, followed by the addition of a second TREM2 antibody. These antibodies compete with each other if the presence of the first TREM2 antibody reduces binding of the second TREM2 antibody in either assay. The term "competes with" also includes antibody combinations where one antibody reduces binding of another antibody, but no competition is observed when the antibodies are added in the reverse order. However, in some embodiments, the first and second antibodies inhibit each other's binding regardless of the order in which they are added. In some embodiments, one antibody reduces the binding of another antibody to its antigen by at least 25%, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, or at least 95%. One skilled in the art can select the concentration of antibody to use in a competition assay based on the affinity of the antibody for TREM2 and the valency of the antibody. The assays set forth in this definition are illustrative and one skilled in the art can utilize any suitable assay to determine whether antibodies compete with each other. Suitable assays are described, for example, in Cox et al., "Immunoassay Methods," in Assay Guidance Manual [Internet], Updated December 24, 2014 (www.ncbi.nlm.nih.gov / books / NBK92434 / ; accessed September 29, 2015), Silman et al., Cytometry, 2001, 44:30-37, and Finco et al., J. Pharm. Biomed. Anal., 2011, 54:351-358, each of which is incorporated by reference in its entirety.

[0186] In some embodiments, the antibodies provided herein have a potency of about 0.001, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 1.95, 2, 3, 4, 5, 6, 7, 8, 9, or 10×10 as measured by a Biacore assay. -9 K below M D In some embodiments, the K of the antibodies provided herein binds to human TREM2. D is about 0.001-0.01, 0.01-0.1, 0.01-0.05, 0.05-0.1, 0.1-0.5, 0.5-1, 0.25-0.75, 0.25-0.5, 0.5-0.75, 0.75-1, 0.75-2, 1.1-1.2, 1.2-1.3, 1.3-1.4, 1.4-1.5, 1.5-1.6, 1.6-1.7, 1.7-1.8, 1.8-1.9, 1.9-2, 1-2, 1-5, 2-7, 3-8, 3-5, 4-6, 5-7, 6-8, 7-9, 7-10, or 5-10 x 10, as measured by a Biacore assay. -9 It's M.

[0187] In some embodiments, the antibodies provided herein have a titer of about 2, 1.98, 1.95, 1.9, 1.85, 1.8, 1.75, 1.7, 1.65, 1.6, 1.55, 1.50, 1.45, or 1.4 x 10 as measured by a Biacore assay. -9 K below or equal to M D In some embodiments, the antibodies provided herein bind to human TREM2 at a binding affinity of 1.9-1.8, 1.8-1.7, 1.7-1.6, 1.6-1.5, or 1.9-1.5 x 10 as measured by a Biacore assay. -9 K of M DIn some embodiments, the antibodies provided herein bind to human TREM2 at about 10, 9.56, 9.5, 9.0, 8.88, 8.84, 8.5, 8, 7.5, 7.32, 7, 6.5, 6, 5.5, 5, 4.5, 4, 3.5, 3, 2.5, 2, 1.5, or 1 x 10 as measured by a Biacore assay. -4 (1 / s) or less K d In some embodiments, the antibodies provided herein bind to human TREM2 at 7-10, 7-8, 8-9, 9-10, 7-7.5, 7.5-8, 8.-8.5, 8.5-9, 9-9.5, or 9.5-10 x 10 as measured by a Biacore assay. -4 (1 / s)K d In some embodiments, the antibodies provided herein bind to human TREM2 with a binding affinity of about 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 45, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 7, 8, 9, or 10×10 as measured by a Biacore assay. 5 (1 / Ms) or more, or K greater a In some embodiments, the antibodies provided herein bind to human TREM2 at 4-7, 4-4.5, 4.5-5, 5-5.5, 5.5-6, 6-6.5, or 6.5-7, 7-8, 8-9, or 9-10 x 10 as measured by a Biacore assay. 5 (1 / Ms)K a Binds to human TREM2 at

[0188] In some embodiments, the antibodies provided herein bind to human TREM2 with an EC50 of 2, 1.9, 1.8, 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, 1.1, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, or 0.1 nM or less as measured by flow cytometry. In some embodiments, the antibodies bind to human TREM2 with an EC50 of 0.6-1.4 nM as measured by flow cytometry. In some embodiments, the antibodies bind to human TREM2 with an EC50 of about 0.5, 0.6, 0.9, 1.1, 1.2, 1.3, 1.4, or 1.5 nM as measured by flow cytometry.

[0189] In some embodiments, the antibodies provided herein bind to human TREM2 with an EC50 of 2, 1.9, 1.8, 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, 1.1, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, or 0.1 nM or less as measured by flow cytometry. In some embodiments, the antibodies bind to mouse TREM2 with an EC50 of 0.6-1.4 nM as measured by flow cytometry. In some embodiments, the antibodies bind to mouse TREM2 with an EC50 of about 0.5, 0.6, 0.9, 1.1, 1.2, 1.3, 1.4, or 1.5 nM as measured by flow cytometry.

[0190] In some embodiments, the antibodies provided herein do not bind to human TREM2 with an EC50 of 20 nM or greater, as measured by flow cytometry. In some embodiments, the antibodies provided herein do not bind to mouse TREM2 with an EC50 of 3 nM or greater, as measured by flow cytometry.

[0191] To screen for antibodies that bind to an epitope on a target antigen bound by an antibody of interest (e.g., TREM2), a conventional cross-blocking assay can be performed, such as that described in Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988). Alternatively, or in addition, epitope mapping can be performed by methods known in the art.

[0192] Competition between antibodies can be determined by an assay in which the antibody under test inhibits or blocks the specific binding of a reference antibody to a common antigen (see, for example, Junghans et al., Cancer Res. 50:1495, 1990; Fendly et al. Cancer Research 50:1550-1558, US6,949,245). If an excess of the test antibody (e.g., at least 2-fold, 5-fold, 10-fold, 20-fold, or 100-fold) inhibits or blocks the binding of the reference antibody by at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or 99%, as measured, for example, by a competitive binding assay, the test antibody competes with the reference antibody. Antibodies identified by competitive assays (competing antibodies) include antibodies that bind to the same epitope as the reference antibody, and antibodies that bind to adjacent epitopes that are sufficiently close to the epitope bound by the reference antibody to cause steric hindrance. For example, a second competing antibody may be identified that competes with a first antibody described herein for binding to TREM2. In certain cases, the second antibody can block or inhibit binding of the first antibody, for example, by at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or 99%, as measured in a competitive binding assay. In certain cases, the second antibody can displace the first antibody by greater than 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or 99%.

[0193] function In some embodiments, the antibody has antibody-dependent cellular cytotoxicity (ADCC) activity. ADCC can occur when an antibody binds to an antigen on the surface of a target cell. Effector cells that have Fc gamma receptors (FcγR or FCGR) on their cell surface, including cytotoxic T cells, natural killer (NK) cells, macrophages, neutrophils, eosinophils, dendritic cells, or monocytes, recognize and bind the Fc region of an antibody bound to a target cell. Such binding can cause activation of intracellular signaling pathways that lead to cell death. In certain embodiments, the immunoglobulin Fc region subtype (isotype) of the antibody includes human IgG1 and IgG3. As used herein, ADCC refers to a cell-mediated reaction in which non-specific cytotoxic cells expressing Fc receptors (FcR), such as natural killer (NK) cells, neutrophils, and macrophages, recognize bound antibodies on target cells and subsequently cause lysis of the target cells. NK cells, the primary cells for mediating ADCC, express only FcγRIII, whereas monocytes express FcγRI, FcγRII, and FcγRIII. FcR expression on hematopoietic cells in summary is given in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991). To assess ADCC activity of a molecule of interest, an in vitro ADCC assay, such as that described in U.S. Pat. No. 5,500,362 or U.S. Pat. No. 5,821,337, may be performed. Effector cells useful for such assays include peripheral blood mononuclear cells (PBMC) and natural killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed in vivo, e.g., in an animal model such as that disclosed in Clynes et al., Proc. Natl. Acad. Sci. (USA) 95:652-656 (1998).

[0194] In some embodiments, the antibody has complement-dependent cytotoxicity (CDC) activity. Antibody-induced CDC is mediated through proteins of the classical complement cascade and is triggered by the binding of the complement protein Clq to the antibody. The antibody Fc region that binds Clq can induce activation of the complement cascade. In certain embodiments, the immunoglobulin Fc region subtype (isotype) of the antibody includes human IgG1 and IgG3. As used herein, CDC refers to the ability of a molecule to lyse a target in the presence of complement. The complement activation pathway is initiated by the binding of the first component of the complement system (C1q) to a molecule (e.g., a polypeptide (e.g., an antibody)) complexed with a cognate antigen. To assess complement activation, a CDC assay may be performed, for example, as described in Gazzano-Santoro et al., J. Immunol. Methods 202:163 (1996).

[0195] In some embodiments, the antibody is an agonist antibody. An agonist antibody can induce (e.g., increase) one or more activities or functions of NSM after the antibody binds to the TREM2 protein expressed on a cell. An agonist antibody can bind to NSM, activate NSM, and cause changes in cell proliferation or modify antigen presentation ability. An agonist antibody can bind to NSM, activate NSM, and trigger intracellular signaling pathways that result in altered cell growth or apoptosis.

[0196] In some embodiments, the antibody is an antagonist antibody. An antagonist antibody can block (e.g., reduce) one or more activities or functions of NSM after the antibody binds to the TREM2 protein expressed on a cell. For example, an antagonist antibody can bind to one or more NSM proteins, block ligand binding to one or more NSM proteins, prevent cell differentiation and proliferation, or alter antigen presentation ability. An antagonist antibody can bind to the TREM2 protein by its ligand, prevent its activation, and alter intracellular signaling pathways that contribute to cell growth and survival.

[0197] In some embodiments, the antibody is a depleting antibody. A depleting antibody is one that kills unstimulated bone marrow cells when contacted through the interaction of the antibody with other immune cells of the molecule. For example, when the antibody binds to cells that have the TREM2 protein, it can engage with complement proteins and induce complement-dependent cell lysis. When the antibody binds to cells that have the TREM2 protein, it can also trigger adjacent cells that have Fc receptors to kill them by antibody-dependent cellular cytotoxicity (ADCC).

[0198] In some embodiments, the antibody is a neutralizing antibody, and the antibody neutralizes one or more biological activities of the NSM. In some embodiments, the TREM2 protein is expressed on the surface of unstimulated bone marrow cells and the antibody recognizes the extracellular domain of the TREM2 protein.

[0199] In some embodiments, the antibody is selective for NSM (binds preferentially to TREM2). In certain embodiments, an antibody that selectively binds to NSM has a dissociation constant (Kd) in the range of 0.0001 nM to 1 μM. In certain embodiments, the antibody specifically binds to an epitope on the TREM2 protein that is conserved across proteins from different species. In another embodiment, selective binding includes, but is not required to be, exclusive binding.

[0200] In one embodiment, an anti-TREM2 antibody bound to its target causes in vivo depletion of unstimulated bone marrow cells to which it binds. In some embodiments, effector proteins induced by clustered antibodies can trigger various responses including release of inflammatory cytokines, regulation of antigen production, endocytosis, or cell death. In one embodiment, the antibody can recruit and activate complement in vivo, or mediate antibody-dependent cellular cytotoxicity (ADCC), or mediate phagocytosis by binding to Fc receptors in vivo. The antibody can also deplete unstimulated bone marrow cells by inducing apoptosis or necrosis of unstimulated bone marrow cells upon binding.

[0201] In some embodiments, abrogation of unstimulated bone marrow cells is accomplished in vitro by a) killing of unstimulated bone marrow cells, b) magnetic bead depletion of unstimulated bone marrow cells, or c) fluorescence activated cell sorting (FACS) sorting of unstimulated bone marrow cells.

[0202] In some embodiments, the antibody is linked or conjugated to an effector molecule.

[0203] In certain embodiments, the antibody is conjugated to a drug.

[0204] Non-stimulated bone marrow cells (NSM) Provided herein are methods and compositions for neutralizing and / or detecting non-stimulated myeloid cells (NSM), including the use of anti-TREM2 antibodies. Also provided herein are methods and compositions for targeting and / or detecting non-stimulated myeloid cells that express NSM proteins.

[0205] Also provided herein are methods and compositions for neutralizing and / or detecting unstimulated bone marrow cells, comprising the use of antibodies directed against non-human homologs of human NSM proteins in the non-human individual.

[0206] As used herein, non-stimulated bone marrow cells are bone marrow cells that are not sufficiently effective in stimulating an immune response (e.g., not as effective in stimulating an immune response as stimulated bone marrow cells). In some embodiments, non-stimulated bone marrow cells are less effective in presenting antigens to T cells or less effective in stimulating antigen-specific T cell responses as compared to stimulated bone marrow cells. In some embodiments, non-stimulated bone marrow cells can exhibit reduced antigen uptake, processing, and / or presentation capabilities to T cells as compared to stimulated bone marrow cells. Non-stimulated bone marrow cells may have reduced or no ability to reprime cytotoxic T lymphocytes or in some cases may be unable to stimulate effective cell killing. Non-stimulated bone marrow cells can exhibit lower expression of genes and cell surface markers involved in antigen processing, antigen presentation, and / or antigen co-stimulation, including but not limited to CD80, CD86, MHCI, and MHCII, as compared to stimulated bone marrow cells.

[0207] Unstimulated bone marrow cells may exhibit lower expression of genes associated with cross-presentation, costimulation, and / or stimulatory cytokines, including, but not limited to, any one or more of TAP1, TAP2, PSMB8, PSMB9, TAPBP, PSME2, ​​CD24a, CD274, BTLA, CD40, CD244, ICOSL, ICAM1, TIM3, PDL2, RANK, FLT3, CSF2RB, CSF2RB2, CSF2RA, IL12b, XCR1, CCR7, CCR2, CCL22, CXCL9, and CCL5, as well as increased expression of the anti-inflammatory cytokine IL-10, when compared to stimulated bone marrow cells. In some embodiments, unstimulated bone marrow cells are dependent on the transcription factor IRF4 and the cytokines GM-CSF or CSF-1 for differentiation and survival. In some embodiments, unstimulated bone marrow cells can contribute to angiogenesis by secreting vascular endothelial growth factor (VEGF) and nitric oxide synthase (NOS), and support cell growth by secreting epidermal growth factor (EGF).

[0208] In some embodiments, the unstimulated bone marrow cells are tumor-associated macrophages (TAMs), neutrophils, monocytes, or dendritic cells (DCs). In some embodiments, the unstimulated bone marrow cells are not dendritic cells (DCs). In some embodiments, the unstimulated bone marrow cells are neutrophils.

[0209] In some embodiments, unstimulated and stimulated bone marrow cells are distinguished based on the markers they express or that they selectively express. Expression of a cell surface marker can be described as "+" or "positive." Absence of a cell surface marker can be described as "-" or "negative." Expression of a cell surface marker can be further described as "high" (cells expressing high levels of the maker) or "low" (cells expressing low levels of the marker), indicating the relative expression of each marker on the cell surface. The levels of the markers can be determined by various methods known in the art, such as immunostaining and FACS analysis, or gel electrophoresis and western blotting.

[0210] In some embodiments, the non-stimulatory bone marrow cells are dendritic cells (DCs). In some embodiments, dendritic cells can be identified by spinous or dendritic morphology. In one embodiment, the non-stimulatory dendritic cells are at least CD45+, HLA-DR+, CD14-, CD11c+, and BDCA1+ (also referred to as DC1 cells). In one embodiment, the non-stimulatory dendritic cells are not CD45+, HLA-DR+, CD14-, CD11c+, and BDCA3+ (also referred to as DC2 cells). In one embodiment, dendritic cells that are CD45+, HLA-DR+, CD14-, CD11c+, and BDCA3+ are stimulatory bone marrow cells.

[0211] In some embodiments, the unstimulated bone marrow cells are unstimulated macrophages. In some embodiments, for example in humans, the unstimulated macrophages are at least CD45+, HLA-DR+, CD14+. In some embodiments, the unstimulated macrophages are at least CD45+ , HLA-DR + , CD14 + , CD11b + In some embodiments, the unstimulated macrophages are at least CD45 + , HLA-DR + , CD14 + , CD11c + In some embodiments, the unstimulated macrophages are at least CD45 + , HLA-DR + , CD14 + , BDCA3 - In some embodiments, the unstimulated macrophages are at least CD45 + , HLA-DR + , CD14 + , BDCA3 - , CD11b + In some embodiments, the unstimulated macrophages are at least CD45 + , HLA-DR + , CD14 + , BDCA3 - , CD11c + In some embodiments, the unstimulated macrophages are at least CD45 + , HLA-DR + , CD14 + , CD11b + , and CD11c + In some embodiments, the unstimulated macrophages are at least CD45 + , HLA-DR + , CD14 + , BDCA3 - , CD11b + , and CD11c + It is.

[0212] In some embodiments, the methods and compositions of the invention are useful for targeting TAMs and DCs in other mammals, such as mice. In such embodiments, mouse TAMs and DCs are contacted with a TREM2 antibody. In one embodiment, for example in mice, macrophages are at least CD45+, HLA-DR+, CD14+, CD11b 高 , and CD11c 低 (also referred to as TAM1). In one embodiment, for example in a mouse, the macrophages are at least CD45+, HLA-DR+, CD14+, CD11b 低 , and CD11c 高 (also called TAM2). 高 The term "macrophage" as used herein refers to a macrophage expressing high levels of CD11b. 低 The term "macrophage" as used herein refers to CD11b 高 It relates to macrophages that express levels of CD11b on their surface that are substantially lower than the levels of CD11c. 高 The term "macrophage" as used herein refers to a macrophage expressing high levels of CD11c. 低 The term "macrophage" as used herein refers to CD11c 高 It concerns macrophages that express levels of CD11c on their surface that are substantially lower than the levels of macrophages.

[0213] In some embodiments, the unstimulated bone marrow cells of the present invention comprise one or more of TAM and DC1 cells.

[0214] In some embodiments, for example in a mouse, the unstimulated bone marrow cells of the invention comprise one or more of TAM1, TAM2, and DC1 cells, hi such embodiments, the unstimulated bone marrow cells of the invention are contacted with a TREM2 antibody.

[0215] In some embodiments, the unstimulated bone marrow cells are bone marrow cells and are intratumor.

[0216] In some embodiments, the unstimulated bone marrow cells are in a population of immune cells that includes stimulated and unstimulated bone marrow cells. In some embodiments, the unstimulated bone marrow cells are in a population of immune cells that includes only unstimulated bone marrow cells. The populations of immune cells of the present invention may be pure, homogenous, heterogeneous, derived from a variety of sources (e.g., diseased tissue, healthy tissue, cell banks), maintained in primary cell culture, maintained in immortalized culture, and / or maintained in ex vivo culture.

[0217] In some embodiments, the unstimulated bone marrow cells are tumor-associated macrophages.

[0218] In some embodiments, the unstimulated bone marrow cells are dendritic cells.

[0219] In some embodiments, the unstimulated bone marrow cells are CD45 + , HLA-DR + , CD14 - , CD11c + , and BDCA1 + In some embodiments, the unstimulated bone marrow cells are CD45 + , HLA-DR + , CD14 - , CD11c + , and BDCA1 + In some embodiments, the unstimulated bone marrow cells are CD45 + , HLA-DR + , CD14 - , CD11c + , and BDCA1 + In some embodiments, the unstimulated bone marrow cells are comprised of cells that are CD45 + , HLA-DR + , CD14 - , CD11c + , and BDCA1 + The present invention consists essentially of cells which are

[0220] In some embodiments, the unstimulated bone marrow cells are CD45 + , HLA-DR + , CD14 + , BDCA3 - In some embodiments, the unstimulated bone marrow cells are CD45 + , HLA-DR + , CD14 + , BDCA3 - In some embodiments, the unstimulated bone marrow cells are CD45 + , HLA-DR + , CD14 + , BDCA3 - In some embodiments, the unstimulated bone marrow cells are comprised of cells that are CD45 + , HLA-DR + , CD14 + , BDCA3 - The present invention consists essentially of cells which are

[0221] In some embodiments, the unstimulated bone marrow cells are CD45 + , HLA-DR + , CD14 + , CD11b + In some embodiments, the unstimulated bone marrow cells are CD45 + , HLA-DR + , CD14 + , CD11b + In some embodiments, the unstimulated bone marrow cells are CD45 + , HLA-DR + , CD14 + , CD11b + In some embodiments, the unstimulated bone marrow cells are comprised of cells that are CD45 + , HLA-DR + , CD14 + , CD11b + The present invention consists essentially of cells which are

[0222] In some embodiments, the unstimulated bone marrow cells are CD45 + , HLA-DR +, CD14 + , CD11c + In some embodiments, the unstimulated bone marrow cells are CD45 + , HLA-DR + , CD14 + , CD11c + In some embodiments, the unstimulated bone marrow cells are CD45 + , HLA-DR + , CD14 + , CD11c + In some embodiments, the unstimulated bone marrow cells are comprised of cells that are CD45 + , HLA-DR + , CD14 + , CD11c + The present invention consists essentially of cells which are

[0223] In some embodiments, the unstimulated bone marrow cells are CD45 + , HLA-DR + , CD14 + , BDCA3 - , and CD11c + In some embodiments, the unstimulated bone marrow cells are CD45 + , HLA-DR + , CD14 + , BDCA3 - , and CD11c + In some embodiments, the unstimulated bone marrow cells are CD45 + , HLA-DR + , CD14 + , BDCA3 - , and CD11c + In some embodiments, the unstimulated bone marrow cells are comprised of cells that are CD45 + , HLA-DR + , CD14 + , BDCA3 - , and CD11c + The present invention consists essentially of cells which are

[0224] In some embodiments, the unstimulated bone marrow cells are CD45 + , HLA-DR+ , CD14 + , BDCA3 - , CD11b + In some embodiments, the unstimulated bone marrow cells are CD45 + , HLA-DR + , CD14 + , BDCA3 - , CD11b + In some embodiments, the unstimulated bone marrow cells are CD45 + , HLA-DR + , CD14 + , BDCA3 - , CD11b + In some embodiments, the unstimulated bone marrow cells are comprised of cells that are CD45 + , HLA-DR + , CD14 + , BDCA3 - , CD11b + The present invention consists essentially of cells which are

[0225] In some embodiments, the unstimulated bone marrow cells are CD45 + , HLA-DR + , CD14 + , CD11b + , and CD11c + In some embodiments, the unstimulated bone marrow cells are CD45 + , HLA-DR + , CD14 + , CD11b + , and CD11c + In some embodiments, the unstimulated bone marrow cells are CD45 + , HLA-DR + , CD14 + , CD11b + , and CD11c + In some embodiments, the unstimulated bone marrow cells are comprised of cells that are CD45 + , HLA-DR + , CD14 + , CD11b + , and CD11c + The present invention consists essentially of cells which are

[0226] In some embodiments, the unstimulated bone marrow cells are CD45 + , HLA-DR + , CD14 + , BDCA3 - , CD11b + , and CD11c + In some embodiments, the unstimulated bone marrow cells are CD45 + , HLA-DR + , CD14 + , BDCA3 - , CD11b + , and CD11c + In some embodiments, the unstimulated bone marrow cells are CD45 + , HLA-DR + , CD14 + , BDCA3 - , CD11b + , and CD11c + In some embodiments, the unstimulated bone marrow cells are comprised of cells that are CD45 + , HLA-DR + , CD14 + , BDCA3 - , CD11b + , and CD11c + The present invention consists essentially of cells which are

[0227] In some embodiments, the unstimulated bone marrow cells are CD45 + , HLA-DR + , CD14 - , CD11c + , and BDCA3 + In some embodiments, the unstimulated bone marrow cells are not CD45 + , HLA-DR + , CD14 - , CD11c + , and BDCA3 + Includes cells that are not

[0228] In some embodiments, for example in mice, unstimulated bone marrow cells express CD45 +, HLA-DR + , CD14 + , CD11b 高 , and CD11c 低 In some embodiments, for example in mice, unstimulated bone marrow cells are CD45 + , HLA-DR + , CD14 + , CD11b 高 , and CD11c 低 In some embodiments, for example in mice, the unstimulated bone marrow cells are CD45 + , HLA-DR + , CD14 + , CD11b 高 , and CD11c 低 In some embodiments, for example in mice, the unstimulated bone marrow cells are comprised of cells that are CD45 + , HLA-DR + , CD14 + , CD11b 高 , and CD11c 低 In such embodiments, unstimulated mouse bone marrow cells are contacted with the TREM2 antibody.

[0229] In some embodiments, for example in mice, unstimulated bone marrow cells express CD45 + , HLA-DR + , CD14 + , CD11b 低 , and CD11c 高 In some embodiments, for example in mice, unstimulated bone marrow cells are CD45 + , HLA-DR + , CD14 + , CD11b 低 , and CD11c 高 In some embodiments, for example in mice, the unstimulated bone marrow cells are CD45 + , HLA-DR + , CD14 + , CD11b 低 , and CD11c 高In some embodiments, for example in mice, the unstimulated bone marrow cells are comprised of cells that are CD45 + , HLA-DR + , CD14 + , CD11b 低 , and CD11c 高 In such embodiments, unstimulated mouse bone marrow cells are contacted with the TREM2 antibody.

[0230] In some embodiments, the unstimulated bone marrow cells are in fibrous tissue, hi some embodiments, the unstimulated bone marrow cells are in liver tissue.

[0231] In some embodiments, the population of immune cells is in fibrotic tissue, hi some embodiments, the population of immune cells is in liver tissue.

[0232] In some embodiments, the unstimulated cells and the stimulated bone marrow cells are in fibrous tissue, hi some embodiments, the unstimulated cells and the stimulated bone marrow cells are in liver tissue.

[0233] In some embodiments, the biological sample comprises a population of immune cells that includes unstimulated bone marrow cells and stimulated bone marrow cells.

[0234] NSM cells can collectively refer to DC1, TAM1, and TAM2 cells that are present in tumor tissue and can be distinguished from other cell types by the expression of their NSM cell markers. For example, genes and associated proteins that are expressed or translated at higher abundance in NSM cells than in SDCs can serve as NSM markers. An exemplary NSM marker is CD11b. Additional exemplary NSM markers are listed in Table A. NSM cells can express TREM2, MS4A7, C5AR1, LYVE1, ABCC3, LILRB4, MRC1 / CD206, SIGLEC1, STAB1, TMEM37, MERTK, and TMEM119 on their cell surface. In some aspects, NSM cells do not express at least one of KIT, CCR7, BATF3, FLT3, ZBTB46, IRF8, BTLA, MYCL1, CLEC9A, BDCA3, and XCR1.

[0235] In one embodiment, the NSM cells express one or more of the NSM marker genes listed in Table A. In another embodiment, the NSM cells express 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or more of the NSM markers listed in Table D. In another embodiment, the NSM cells express most or all of the NSM markers listed in Table D. In another embodiment, the NSM cells are identified as expressing MRC1, MS4A7, C1QC, APOE, C1QB, C1QA, and C5AR1.

[0236] [Table D]

[0237] Stimulating bone marrow cells As used herein, stimulatory bone marrow cells (also referred to in certain aspects as SDCs) are bone marrow cells that are effective in stimulating an immune response (e.g., more effective in stimulating an immune response compared to non-stimulatory bone marrow cells). In some embodiments, stimulatory bone marrow cells are more effective in presenting antigens to T cells or more effective in stimulating a specific T cell response compared to non-stimulatory bone marrow cells. In some embodiments, stimulatory bone marrow cells can exhibit increased antigen uptake, processing, and / or presentation capacity to T cells compared to non-stimulatory bone marrow cells. Stimulatory bone marrow cells can have increased capacity to reprime cytotoxic T lymphocytes or, in some cases, stimulate effective cell killing compared to non-stimulatory bone marrow cells. Stimulatory bone marrow cells can exhibit higher expression of genes and cell surface markers involved in antigen processing, antigen presentation, and / or antigen co-stimulation, including, but not limited to, CD80, CD86, MHCI, and MHCII, compared to stimulatory bone marrow cells.

[0238] Exemplary stimulatory myeloid cell markers are listed in Table A. For example, in human SDC, expression of Xcr1, Clec9a, and BDCA3 (CD141) are markers of SDC identity. Note that in mice, CD103 can also be used as a strong marker of SDC identity, although it is not expressed in human SDC.

[0239] In one embodiment, SDCs are myeloid cells that have a dendritic cell identity and also express one or more of the SDC markers listed in Table A. In another embodiment, SDCs are myeloid cells that have a dendritic cell identity and also express two, three, four, five, six, seven, eight, nine, or all of the SDC markers listed in Table A. In another embodiment, SDCs are identified as myeloid dendritic cells that express BDCA3, KIT, CCR7, BATF3, FLT3, ZBTB46, IRF8, BTLA, MYCL1, XCR1, and CLEC9A. Cells of SDCs can express at least one of KIT, CCR7, BATF3, FLT3, ZBTB46, IRF8, BTLA, MYCL1, CLEC9A, BDCA3, and XCR1. In some embodiments, SDCs do not substantially express TREM2, MS4A7, C5AR1, LYVE1, ABCC3, LILRB4, MRC1 / CD206, SIGLEC1, STAB1, TMEM37, MERTK, and / or TMEM119 on their cell surface. In some embodiments, SDCs do not substantially express C5AR1, LYVE1, ABCC3, MRC1, SIGLEC1, STAB1, C1QB, C1QA, TMEM37, MERTK, C1QC, TMEM119, MS4A7, APOE, CYP4F18, TREM2, TLR7, and / or LILRB4. Flow cytometry and PCR, among other art-recognized assays, can be used to assess expression of the markers disclosed herein.

[0240] Stimulatory bone marrow cells express CD45 + , HLA-DR + , CD14 - , CD11c + , and BDCA3 + The stimulatory bone marrow cells may be CD45 + , HLA-DR + , and BDCA3 + The stimulatory bone marrow cells may be CD45 + , HLA-DR + , CD14 - , and BDCA3 + The stimulatory bone marrow cells may be CD45+ , HLA-DR + , CD11c + , and BDCA3 + It could be.

[0241] Proteins, nucleotides, and homologs Provided herein are methods and compositions for invalidating and / or detecting unstimulated human bone marrow cells expressing NSM proteins. In some embodiments, the invention is directed to invalidating and / or detecting unstimulated bone marrow cells from non-human mammalian cells expressing NSM protein homologs. For example, NSM proteins in mice can express a restricted expression pattern equivalent to their human homologs. Thus, in one embodiment, provided herein are methods and compositions for invalidating and / or detecting unstimulated mouse bone marrow cells expressing NSM proteins. Also provided herein are similar methods and compositions for invalidating and / or detecting unstimulated cells from any individual expressing a homolog of an NSM protein with an expression pattern similar to that of the homolog of the NSM protein, where these cells show an expression pattern equivalent to that of the NSM protein.

[0242] The NSM proteins or nucleotides may include at least one or more of C5AR1, LYVE1, ABCC3, MRC1, SIGLEC1, STAB1, C1QB, C1QA, TMEM37, MERTK, C1QC, TMEM119, MS4A7, APOE, CYP4F18, TREM2, TLR7, and LILRB4, and homologs thereof. The SDC proteins or nucleotides may include at least one or more of KIT, CCR7, BATF3, FLT3, ZBTB46, IRF8, BTLA, MYCL1, CLEC9A, BDCA3, and XCR1, and homologs thereof. The cell surface NSM proteins may include at least one or more of TREM2, MS4A7, C5AR1, LYVE1, ABCC3, LILRB4, MRC1 / CD206, SIGLEC1, STAB1, TMEM37, MERTK, and TMEM119. Cell surface NSM proteins can be targeted by one or more anti-TREM2 antibodies, either alone or in combination. In general, NSM is positive for NSM proteins or nucleotides, and negative for SDC proteins or nucleotides. Conversely, SDC is generally positive for SDC proteins or nucleotides, and negative for NSM proteins or nucleotides.

[0243] The antibodies described herein comprise at least one polypeptide, but typically comprise a dimer of HC / LC, i.e., four polypeptides. Polynucleotides encoding the polypeptides described herein are also described. Antibodies are typically isolated.

[0244] As used herein, "isolated" refers to an agent (e.g., a polypeptide or polynucleotide) that has been identified and separated and / or recovered from components of its natural cell culture environment. Contaminant components of its natural environment are materials that would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes. Isolated can also refer to an agent that has been produced synthetically, for example, by human intervention.

[0245] The terms "polypeptide", "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. That is, a description of a polypeptide applies equally to a description of a peptide and a description of a protein, and vice versa. These terms apply to naturally occurring amino acid polymers and to amino acid polymers in which one or more amino acid residues are non-naturally encoded amino acids. As used herein, the terms encompass amino acid chains of any length, including full-length proteins, in which the amino acid residues are linked by covalent peptide bonds.

[0246] The term "amino acid" refers to naturally occurring and non-naturally occurring amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to naturally occurring amino acids. Naturally encoded amino acids are the 20 common amino acids (alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, praline, serine, threonine, tryptophan, tyrosine, and valine) as well as pyrrolysine and selenocysteine. Amino acid analogs refer to compounds that have the same basic chemical structure as naturally occurring amino acids, i.e., carbons that are attached to hydrogen, carboxyl groups, amino groups, and R groups such as homoserine, norleucine, methionine sulfoxide, and methionine methylsulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as naturally occurring amino acids. Reference to amino acids includes, for example, naturally occurring proteinogenic L-amino acids, D-amino acids, chemically modified amino acids such as amino acid variants and derivatives, naturally occurring non-proteinogenic amino acids such as β-alanine, ornithine, and chemically synthesized compounds having properties known in the art to be characteristic of amino acids. Examples of non-naturally occurring amino acids include, but are not limited to, α-methyl amino acids (e.g., α-methylalanine), D-amino acids, histidine-like amino acids (e.g., 2-amino-histidine, β-hydroxy-histidine, homohistidine), amino acids with an extra methylene in the side chain ("homo" amino acids), and amino acids in which the carboxylic acid functional group in the side chain is replaced with a sulfonic acid group (e.g., cysteic acid). Incorporating non-naturally occurring amino acids, including synthetic non-naturally occurring amino acids, substituted amino acids, or one or more D-amino acids, into the proteins of the invention can be advantageous in many different ways. D-amino acid-containing peptides and the like exhibit increased stability in vitro or in vivo compared to their L-amino acid-containing counterparts.Therefore, constructing peptides and the like incorporating D-amino acids can be particularly useful when greater intracellular stability is desired or required.More specifically, D-peptides and the like are resistant to endogenous peptidases and proteases, thereby providing improved bioavailability of molecules and extended life span in vivo when such properties are desired.In addition, D-peptides and the like cannot be efficiently processed for major histocompatibility complex class II restricted presentation to T helper cells, and therefore are less likely to induce humoral immune responses in whole organisms.

[0247] Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides may also be referred to by their commonly accepted single-letter codes.

[0248] The present invention also includes polynucleotides that code for antibody polypeptides. The term "polynucleotide" or "nucleotide sequence" is intended to indicate a contiguous stretch of two or more nucleotide molecules. The nucleotide sequence may be of genomic, cDNA, RNA, semisynthetic or synthetic origin, or any combination thereof.

[0249] The term "nucleic acid" refers to deoxyribonucleotides, deoxyribonucleosides, ribonucleosides, or ribonucleotides, and polymers thereof, in either single-stranded or double-stranded form. Unless otherwise limited, the term encompasses nucleic acids containing known analogs of natural nucleotides that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise limited, the term also refers to oligonucleotide analogs, including PNAs (peptide nucleic acids), analogs of DNA used in antisense technology (phosphorothioates, phosphoramidates, etc.). Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses its conservatively modified variants (including but not limited to degenerate codon substitutions) and complementary sequences, as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions can be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)).

[0250] "Conservatively modified variants" applies to both amino acid and nucleic acid sequences. With respect to a particular nucleic acid sequence, "conservatively modified variants" refers to nucleic acids that code for identical or essentially identical amino acid sequences, or where the nucleic acid does not code for an amino acid sequence in an essentially identical sequence. Due to the degeneracy of the genetic code, a large number of functionally identical nucleic acids code for any given protein. For example, the codons GCA, GCC, GCG, and GCU all code for the amino acid alanine. Thus, at every position where alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations," which are one species of conservatively modified variations. Every nucleic acid sequence herein that codes for a polypeptide also describes every possible silent variation of the nucleic acid. One of skill in the art will recognize that each codon in a nucleic acid (except AUG, which is usually the only codon for methionine, and TGG, which is usually the only codon for tryptophan) can be modified to result in a functionally identical molecule. Thus, every silent variation of a nucleic acid that codes for a polypeptide is implicit in every sequence described.

[0251] With respect to amino acid sequences, one of skill in the art will recognize that individual substitutions, deletions, or additions to a nucleic acid, peptide, polypeptide, or protein sequence that modify, add, or delete a single amino acid or a small percentage of amino acids in the encoded sequence are "conservatively modified variants," modifications that result in the deletion of an amino acid, the addition of an amino acid, or the replacement of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are known to those of skill in the art. Such conservatively modified variants are in addition to, and do not exclude, polymorphic variants, interspecies homologs, and alleles as described herein.

[0252] Conservative substitution tables providing functionally similar amino acids are known to those of skill in the art. The following eight groups each contain amino acids that are conservative substitutions for one another: 1) alanine (A), glycine (G), 2) aspartic acid (D), glutamic acid (E), 3) asparagine (N), glutamine (Q), 4) arginine (R), lysine (K), 5) isoleucine (I), leucine (L), methionine (M), valine (V), 6) phenylalanine (F), tyrosine (Y), tryptophan (W), 7) serine (S), threonine (T), and 8) cysteine ​​(C), methionine (M) (see, e.g., Creighton, Proteins: Structures and Molecular Properties (WH Freeman & Co.; 2nd edition (December 1993)).

[0253] The term "identical" or percent "identity" refers to two or more sequences or subsequences that are the same with respect to two or more nucleic acid or polypeptide sequences. Sequences are "substantially identical" if they have the same percentage of amino acid residues or nucleotides (i.e., about 60% identity, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95% identity over a specified region) when compared and aligned for maximum correspondence over a comparison window or specified region, as measured using one of the following sequence comparison algorithms (or other algorithms available to those skilled in the art) or by manual alignment and visual inspection. Alignment for purposes of determining percent amino acid sequence identity can be accomplished in a variety of ways that are within the skill of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, MEGALIGN (DNASTAR), CLUSTALW, CLUSTAL OMEGA, or MUSCLE software. This definition also refers to the complement of the test sequence. The identity may be over a region of at least about 50 amino acids or nucleotides in length, or over a region of 75-100 amino acids or nucleotides in length, or, if not specified, over the entire sequence of the polynucleotide or polypeptide. Polynucleotides encoding the polypeptides of the invention, including homologs from species other than human, may be obtained by a process comprising screening a library under stringent hybridization conditions with a labeled probe having a polynucleotide sequence described herein or a fragment thereof to isolate full-length cDNA and genomic clones containing the polynucleotide sequence described above. Such hybridization techniques are well known to those skilled in the art.

[0254] For sequence comparison, typically, one sequence serves as a reference sequence, and test sequences are compared with it.When using sequence comparison algorithm, test sequences and reference sequences are input into computer, subsequence coordinates are designated as necessary, and sequence algorithm program parameters are designated.Default program parameters can be used, or alternative parameters can be designated.The sequence comparison algorithm then calculates the percent sequence identity of test sequences to reference sequences based on program parameters.

[0255] A "comparison window", as used herein, includes reference to any one segment of the number of contiguous positions selected from the group consisting of 20 to 600, usually about 50 to about 200, more usually about 100 to about 150, within which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are known to those of skill in the art. Optimal alignment of sequences for comparison can be performed, without limitation, by the local homology algorithm of Smith and Waterman (1970) Adv. Appl. Math. 2:482c, by the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443, by the search for similarity method of Pearson and Lipman (1988) Proc. Nat'l. Acad. Sci. USA 85:2444, by computer implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by manual alignment and visual inspection (see, e.g., Ausubel et al., Current Protocols in Molecular Biology (1995 supplement)).

[0256] One example of a suitable algorithm for determining percent sequence identity and sequence similarity is the BLAST and BLAST 2.0 algorithms, described in Altschul et al. (1997) Nuc. Acids Res. 25:3389-3402, and Altschul et al. (1990) J. Mol. Biol. 215:403-410, respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information, available on the World Wide Web at ncbi.nlm.nih.gov. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=-4, and a comparison of both strands. For amino acid sequences, the BLASTP program uses a wordlength of 3, and an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1992) Proc. Natl. Acad. Sci. USA 89:10915) alignments (B) of 50, an expectation (E) of 10, M=5, N=-4, and a comparison of both strands. The BLAST algorithm is typically run with the "low complexity" filter turned off.

[0257] BLAST algorithm also performs statistical analysis of the similarity between two sequences (see, for example, Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5787). One measure of similarity provided by BLAST algorithm is the minimum sum probability (P(N)), which provides an indication of the probability that a match between two nucleotide or amino acid sequences will occur by chance. For example, a nucleic acid is considered to be similar to a reference sequence if the minimum sum probability in the comparison between the test nucleic acid and the reference nucleic acid is less than about 0.2, or less than about 0.01, or less than about 0.001.

[0258] The phrase "selectively (or specifically) hybridizes to" refers to a molecule that binds, duplexes, or hybridizes only to a particular nucleotide sequence under stringent hybridization conditions when that sequence is present in a complex mixture (including, but not limited to, total cellular or library DNA or RNA).

[0259] The phrase "stringent hybridization conditions" refers to hybridization of DNA, RNA, or other nucleic acid sequences, or combinations thereof, under conditions of low ionic strength and high temperature, as known in the art. Typically, under stringent conditions, a probe will hybridize to its target sequence in a complex mixture of nucleic acids (including, but not limited to, total cellular or library DNA or RNA), but not to other sequences in the complex mixture. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to nucleic acid hybridization can be found in Tijssen, Laboratory Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Probes, "Overview of principles of hybridization and the strategy of nucleic acid assays" (1993).

[0260] As used herein, the terms "engineer, engineered, engineering" are considered to include any manipulation of the peptide backbone or post-translational modification of a naturally occurring or recombinant polypeptide or fragment thereof. Engineering includes alterations of the amino acid sequence, glycosylation patterns, or side groups of individual amino acids, as well as combinations of these approaches. Engineered proteins are expressed and produced by standard molecular biology techniques.

[0261] By "isolated nucleic acid molecule or polynucleotide" is intended a nucleic acid molecule, DNA or RNA, that has been removed from its natural environment. For example, a recombinant polynucleotide encoding a polypeptide contained in a vector is considered isolated. Further examples of isolated polynucleotides include recombinant polynucleotides maintained in heterologous host cells or polynucleotides purified (partially or substantially) in solution. An isolated polynucleotide includes a polynucleotide molecule that is normally contained in a cell that contains the polynucleotide molecule, but the polynucleotide molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location. Isolated RNA molecules include in vivo or in vitro RNA transcripts, and positive and negative stranded forms, as well as double-stranded forms. The isolated polynucleotides or nucleic acids described herein further include such molecules that are synthetically produced, for example, via PCR or chemical synthesis. In addition, in certain embodiments, the polynucleotide or nucleic acid includes regulatory elements such as a promoter, a ribosome binding site, or a transcription terminator.

[0262] The term "polymerase chain reaction" or "PCR" generally refers to a method for amplifying a desired nucleotide sequence in vitro, for example, as described in U.S. Patent No. 4,683,195. In general, the PCR method involves repeated cycles of primer extension synthesis using oligonucleotide primers capable of preferentially hybridizing to a template nucleic acid.

[0263] A nucleic acid or polynucleotide having a nucleotide sequence that is at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention is intended to mean that the nucleotide sequence of the polynucleotide is identical to the reference sequence, except that the polynucleotide sequence may contain up to 5 point mutations for every 100 nucleotides of the reference nucleotide sequence.In other words, to obtain a polynucleotide having a nucleotide sequence that is at least 95% identical to the reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or replaced with another nucleotide, or up to 5% of the number of nucleotides of the total nucleotides in the reference sequence may be inserted into the reference sequence.These changes in the reference sequence may occur at the 5' or 3' terminal position of the reference nucleotide sequence, or anywhere between these terminal positions, and may be either interspersed between the residues in the reference sequence individually, or interspersed within one or more consecutive groups in the reference sequence. As a practical matter, whether any particular polynucleotide sequence is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to a nucleotide sequence of the invention can be routinely determined using known computer programs, such as those discussed above for polypeptides (e.g., ALIGN-2).

[0264] A derivative or variant of a polypeptide is said to share "homology" or be "homologous" to a peptide if the amino acid sequence of the derivative or variant has at least 50% identity with the sequence of 100 amino acids from the original peptide. In certain embodiments, the derivative or variant is at least 75% identical to either the peptide or a fragment of the peptide having the same number of amino acid residues as the derivative. In certain embodiments, the derivative or variant is at least 85% identical to either the peptide or a fragment of the peptide having the same number of amino acid residues as the derivative. In certain embodiments, the amino acid sequence of the derivative is at least 90% identical to either the peptide or a fragment of the peptide having the same number of amino acid residues as the derivative. In some embodiments, the amino acid sequence of the derivative is at least 95% identical to either the peptide or a fragment of the peptide having the same number of amino acid residues as the derivative. In certain embodiments, the derivative or variant is at least 99% identical to either the peptide or a fragment of the peptide having the same number of amino acid residues as the derivative.

[0265] The term "modified" as used herein refers to any alteration made to a given polypeptide, such as a change in the length, amino acid sequence, chemical structure, co-translational modification, or post-translational modification of the polypeptide. The term in the form "(modified)" means that the polypeptide under consideration is optionally modified, i.e., the polypeptide under consideration may or may not be modified.

[0266] In some aspects, a polypeptide comprises an amino acid sequence that is at least 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identical to the relevant (e.g., polypeptide and / or antibody) amino acid sequence, or a fragment thereof, set forth in the table(s) or accession number(s) disclosed herein. In some aspects, an isolated antibody or protein disclosed herein comprises an amino acid sequence encoded by a polynucleotide that is at least 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identical to the relevant nucleotide sequence, or a fragment thereof, set forth in the table(s) or accession number(s) disclosed herein. In some embodiments, the nucleotide sequence comprises a nucleotide sequence that is at least 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identical to a nucleotide sequence disclosed herein, such as those set forth in the table(s) or accession number(s) disclosed herein.

[0267] Pharmaceutical Compositions The present application provides compositions comprising antibodies, including pharmaceutical compositions comprising any one or more of the antibodies described herein, together with one or more pharma- ceutically acceptable excipients. In some embodiments, the compositions are sterile. Pharmaceutical compositions generally comprise an effective amount of antibodies.

[0268] These compositions may contain, in addition to one or more of the antibodies disclosed herein, pharma- ceutically acceptable excipients, carriers, buffers, stabilizers, or other materials known to those skilled in the art. Such materials must be non-toxic and must not interfere with the effectiveness of the active ingredient. The exact nature of the carrier or other materials may depend on the route of administration, for example, oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular, intraperitoneal routes.

[0269] Whether it is a polypeptide, an antibody (e.g., an anti-TREM2 antibody), a nucleic acid, a small molecule, or other pharma- ceutical useful compound given to an individual, administration is preferably in a "therapeutically effective amount" or a "prophylactically effective amount" (although in some cases prophylaxis can be considered therapy), which is sufficient to show benefit to the individual. The actual amount administered, and the rate and time course of administration, will depend on the nature and severity of the protein aggregation disorder being treated. Prescription of treatment, e.g., determining dosage, etc., is within the responsibility of general practitioners and other physicians, and typically takes into account the disorder being treated, the condition of the individual subject, the site of delivery, the method of administration, and other factors known to the practitioner. Examples of the techniques and protocols mentioned above can be found in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. (ed), 1980.

[0270] The compositions may be administered alone or in combination with other treatments, either simultaneously or sequentially, depending on the condition to be treated.

[0271] method Preparation method The antibodies described herein can be produced using recombinant methods and compositions, for example, as described in US Pat. No. 4,816,567.

[0272] In one embodiment, an isolated nucleic acid is provided that encodes an antibody described herein. Such a nucleic acid may encode an amino acid sequence comprising the VL of the antibody and / or an amino acid sequence comprising the VH of the antibody (e.g., the light and / or heavy chain of the antibody), or an amino acid sequence comprising the VHH of a single domain antibody. In a further embodiment, one or more vectors (e.g., expression vectors) comprising such a nucleic acid are provided. In one embodiment, the nucleic acid is provided in a multicistronic vector. In a further embodiment, a host cell comprising such a nucleic acid is provided. In one such embodiment, the host cell comprises (e.g., has been transformed with): (1) a vector comprising a nucleic acid encoding an amino acid sequence comprising the VL of the antibody and an amino acid sequence comprising the VH of an antigen-binding polypeptide construct, or (2) a first vector comprising a nucleic acid encoding an amino acid sequence comprising the VL of an antigen-binding polypeptide construct, and a second vector comprising a nucleic acid encoding an amino acid sequence comprising the VH of an antigen-binding polypeptide construct. In one embodiment, the host cell is a eukaryotic cell, such as a Chinese hamster ovary (CHO) cell, or a human embryonic kidney (HEK) cell, or a lymphocytic cell (e.g., a Y0, NS0, Sp20 cell). In one embodiment, a method of making an antibody is provided, the method comprising culturing a host cell comprising an antibody-encoding nucleic acid as provided above under conditions suitable for expression of the antibody, and optionally recovering the antibody from the host cell (or host cell culture medium).

[0273] For recombinant production of an antibody, for example, nucleic acid encoding the antibody, as described above, is isolated and inserted into one or more vectors for further cloning and / or expression in a host cell. Such nucleic acid can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody).

[0274] The term "substantially purified" refers, in certain embodiments, to a construct described herein, or a variant thereof, which may be substantially or essentially free of components that normally accompany or interact with the protein as found in its naturally occurring environment, i.e., native or host cell, in the case of a recombinantly produced heteromultimer that is substantially free of cellular material, and includes preparations of the protein having less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 4%, less than about 3%, less than about 2%, or less than about 1% (by dry weight) of contaminating protein. When the heteromultimer or variant thereof is recombinantly produced by a host cell, in certain embodiments, the protein is present at no more than about 30%, about 25%, about 20%, about 15%, about 10%, about 5%, about 4%, about 3%, about 2%, or about 1% of the dry weight of the cell. When the heteromultimer or variant thereof is recombinantly produced by a host cell, in certain embodiments, the protein is present in the culture medium at about 5 g / L, about 4 g / L, about 3 g / L, about 2 g / L, about 1 g / L, about 750 mg / L, about 500 mg / L, about 250 mg / L, about 100 mg / L, about 50 mg / L, about 10 mg / L, or less than about 1 mg / L of dry weight of the cells. In certain embodiments, a "substantially purified" heteromultimer produced by the methods described herein has a purity level of at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, specifically at least about 75%, 80%, 85%, more specifically at least about 90%, at least about 95%, at least about 99% or more, as determined by suitable methods such as SDS / PAGE analysis, RP-HPLC, SEC, and capillary electrophoresis.

[0275] Suitable host cells for cloning or expressing the antibody-encoding vectors include prokaryotic or eukaryotic cells described herein.

[0276] "Recombinant host cell" or "host cell" refers to a cell that contains an exogenous polynucleotide, regardless of the method used for insertion, such as direct uptake, transduction, f-mating, or other methods known in the art to generate a recombinant host cell. The exogenous polynucleotide may be maintained as a non-integrated vector, such as a plasmid, or alternatively, may be integrated into the host genome. Host cells may include CHO, derivatives of CHO, NS0, Sp2O, CV-1, VERO-76, HeLa, HepG2, Per.C6, or BHK.

[0277] As used herein, the term "eukaryote" refers to organisms belonging to phylogenetic domains such as animals (including but not limited to mammals, insects, reptiles, birds, etc.), ciliates, plants (including but not limited to monocots, dicots, algae, etc.), fungi, yeasts, flagellates, microsporophytes, and protists.

[0278] As used herein, the term "prokaryote" refers to a prokaryotic organism. For example, non-eukaryotic organisms include those from the Eubacteria (including, but not limited to, Escherichia coli, Thermus thermophilus, Bacillus stearothermophilus, Pseudomonas fluorescens, Pseudomonas aeruginosa, Pseudomonas putida, etc.) phylogenetic domain, or Archaea (Methanococcus jannaschii, Methanobacterium thermoautotrophicum, Halobacterium, e.g., Haloferax volcanii, etc.) phylogenetic domain. volcanii and Halobacterium genus species NRC-1, Archaeoglobus fulgidus, Pyrococcus furiosus, Pyrococcus horikoshii, Aeuropyrum pernix, etc.) may belong to the phylogenetic domain.

[0279] For example, antibodies can be produced in bacteria, particularly if glycosylation and Fc effector functions are not required. For expression of antibody fragments and polypeptides in bacteria, see, e.g., U.S. Patent Nos. 5,648,237, 5,789,199, and 5,840,523. (See also Charlton, Methods in Molecular Biology, Vol. 248 (BKC Lo, ed., Humana Press, Totowa, NJ, 2003), pp. 245-254, which describes the expression of antibody fragments in E. coli.) After expression, the antibody may be isolated from the bacterial cell paste in a soluble fraction and may be further purified.

[0280] In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors, including fungal and yeast strains in which the glycosylation pathway has been "humanized," resulting in the production of antibodies with partial or fully human glycosylation patterns. See Gerngross, Nat. Biotech. 22:1409-1414 (2004), and Li et al., Nat. Biotech. 24:210-215 (2006).

[0281] Suitable host cells for the expression of glycosylated antibodies are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plants and insect cells. In particular, a number of baculovirus strains have been identified that can be used in conjunction with insect cells for transfection of Spodoptera frugiperda cells.

[0282] Plant cell cultures can also be used as hosts. See, e.g., U.S. Patent Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (which describe the PLANTIBODIES™ technology for producing antibodies in transgenic plants).

[0283] Vertebrate cells may also be used as hosts. For example, mammalian cell lines that are adapted to grow in suspension may be useful. Other examples of useful mammalian host cell lines include SV40 transformed monkey kidney CV1 line (COS-7), human embryonic kidney lines (e.g., 293 or 293 cells, as described in Graham et al., J. Gen Virol. 36:59 (1977)), baby hamster kidney cells (BHK), mouse Sertoli cells (TM4 cells, as described in Mather, Biol. Reprod. 23:243-251 (1980)), monkey kidney cells (CV1), African green monkey kidney cells (VERO-76), human cervical carcinoma cells (HELA), canine kidney cells (MDCK, buffalo rat hepatocytes (BRL 3A), human lung cells (W138), human hepatocytes (Hep G2), mouse mammary tumor (MMT 060562), e.g., Mather et al., Annals Other useful mammalian host cell lines include TRI cells, MRC5 cells, and FS4 cells, as described in NYAcad.Sci.383:44-68 (1982). - These include Chinese hamster ovary (CHO) cells, including CHO cells (Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)), and myeloma cell lines such as Y0, NS0 and Sp2 / 0. For a review of certain mammalian host cell lines suitable for antibody production, see, e.g., Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (BKC Lo, ed., Humana Press, Totowa, NJ), pp. 255-268 (2003).

[0284] In one embodiment, the antibodies described herein are produced in stable mammalian cells by a method comprising transfecting at least one stable mammalian cell with nucleic acids encoding the antibody in a predetermined ratio and expressing the nucleic acids in the at least one mammalian cell. In some embodiments, the predetermined ratio of nucleic acids is determined in a transient transfection experiment to determine the relative ratio of input nucleic acids that results in the highest percentage of antibody in the expression product.

[0285] In some embodiments, the methods of producing antibodies in stable mammalian cells described herein, wherein the expression product of at least one stable mammalian cell comprises a higher proportion of monomeric heavy or light chain polypeptides or desired glycosylated antibodies compared to other antibodies.

[0286] In some embodiments, a method of producing a glycosylated antibody in a stable mammalian cell as described herein, the method comprising identifying and purifying a desired glycosylated antibody, in some embodiments, said identifying is by one or both of liquid chromatography and mass spectrometry.

[0287] If necessary, the antibody may be purified or isolated after expression. Proteins may be isolated or purified in a variety of ways known to those skilled in the art. Standard purification methods include chromatographic techniques including ion exchange, hydrophobic interaction, affinity, sizing or gel filtration, and reversed phase, performed at atmospheric or elevated pressure using systems such as FPLC and HPLC. Purification methods also include electrophoretic, immunological, precipitation, dialysis, and chromatofocusing techniques. Ultrafiltration and diafiltration techniques are also useful in conjunction with protein concentration. As is well known in the art, a variety of natural proteins bind to Fc and antibodies, and these proteins may find use in the present invention for the purification of antibodies. For example, bacterial proteins A and G bind to the Fc region. Similarly, bacterial protein L binds to the Fab region of some antibodies. Purification can often be made possible by specific fusion partners, for example, glutathione resins when using GST fusions, Ni when using His tags, and β-lactams. +2 Antibodies may be purified using affinity chromatography or, if a Flag tag is used, immobilized anti-Flag antibodies. For general guidance on suitable purification techniques, see, for example, reference Protein Purification: Principles and Practice, 3, incorporated by reference in its entirety. rd Ed., Scopes, Springer-Verlag, NY, 1994. The degree of purification required will vary depending on the use of the antibody. In some cases, no purification is necessary.

[0288] In certain embodiments, antibodies are purified using anion exchange chromatography, including but not limited to, chromatography on Q-Sepharose, DEAE Sepharose, poros HQ, poros DEAF, Toyopearl Q, Toyopearl QAE, Toyopearl DEAE, Resource / Source Q and DEAE, Fractogel Q and DEAE columns.

[0289] In certain embodiments, the proteins described herein are purified using cation exchange chromatography, including, but not limited to, SP-Sepharose, CM Sepharose, poros HS, poros CM, Toyopearl SP, Toyopearl CM, Resource / Source S and CM, Fractogel S and CM columns, and their equivalents and comparables.

[0290] In addition, the antibodies described herein can be chemically synthesized using techniques known in the art (see, e.g., Creighton, 1983, Proteins: Structures and Molecular Principles, WH Freeman & Co., NY and Hunkapiller et al., Nature, 310:105-111 (1984)). For example, a polypeptide corresponding to a fragment of a polypeptide can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the polypeptide sequence. Non-classical amino acids include, but are not limited to, D-isomers of common amino acids, 2,4-diaminobutyric acid, alpha-aminoisobutyric acid, 4 aminobutyric acid, Abu, 2-aminobutyric acid, g-Abu, e-Ahx, 6 aminohexanoic acid, Aib, 2-aminoisobutyric acid, 3-aminopropionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, alanine, fluoro-amino acids, designer amino acids such as methyl amino acids, C-methyl amino acids, N-methyl amino acids, and common amino acid analogs. Additionally, amino acids can be D (dextrorotatory) or L (levorotatory).

[0291] How to use In one aspect, the application provides a method of treating a fibrotic disease or condition in a subject, comprising administering an isolated antibody that binds to human TREM2 (SEQ ID NO: 15) and competes with the 37017 antibody (SEQ ID NO: 31 and 32) for binding to mouse TREM2 (SEQ ID NO: 17), or a method of killing, disabling or depleting TREM2+ bone marrow cells in a subject having a fibrotic disease or condition, comprising contacting bone marrow cells with an isolated antibody that binds to human TREM2 (SEQ ID NO: 15) and optionally competes with the 37017 antibody (SEQ ID NO: 31 and 32) for binding to mouse TREM2 (SEQ ID NO: 17).

[0292] In some embodiments, the antibody comprises: CDR-H1 comprising the sequence set forth in SEQ ID NO: 9, 37, 43, 44, 45, or 46; CDR-H2 comprising the sequence set forth in SEQ ID NO: 10, 47, 48, 49, or 50; A CDR-H3 comprising a sequence as set forth in SEQ ID NO: 11, 39, 51, or 52; CDR-L1 comprising the sequence set forth in SEQ ID NO: 12, 40, 53, or 54; CDR-L2 comprising the sequence shown in SEQ ID NO: 13 or 55; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 14, 42, or 57.

[0293] In some embodiments, administration of a TREM2 antibody reduces fibrosis in a subject compared to administration of an isotype control antibody. For example, administration of a TREM2 antibody can reduce fibrosis in a subject by at least about 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, or 100-fold or more, or 1-2-fold, 2-3-fold, 3-4-fold, 4-5-fold, 5-6-fold, 6-7-fold, 7-8-fold, 8-9-fold, 9-10-fold, 10-20-fold, 20-30-fold, 30-40-fold, 40-50-fold, 50-60-fold, 60-70-fold, 70-80-fold, 80-90-fold, 90-100-fold or more, compared to administration of an isotype control antibody. In other examples, administration of a TREM2 antibody reduces fibrosis in a subject by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, The reduction in fibrosis may be greater than 1000%, or greater than 1-10%, 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, or greater than 90-100%, 100-200%, 200-300%, 300-400%, 400-500%, 500-600%, 600-700%, 700-800%, 800-900%, 900-1000%. Reduction in fibrosis may be determined by any non-invasive assay known to those of skill in the art, such as liver biopsy or serum assays for liver biomarkers or imaging. Such a non-invasive assay is described in Papastergiou et al, Non-invasive assessment of liver fibrosis, Ann Gastroenterol. 2012;25(3):218-231, which is incorporated by reference in its entirety.

[0294] In some embodiments, provided herein is a method of treating fibrosis in a subject in need thereof, comprising administering an effective amount of a means for binding to, depleting, neutralizing or killing TREM2-expressing (TREM2+) cells, wherein the amount of the means for binding to, depleting, neutralizing or killing TREM2+ cells is effective to promote apoptosis in the TREM2+ cells, thereby depleting, neutralizing or killing the cells, thereby treating fibrosis in a subject. In some embodiments, provided herein is a method of treating fibrosis in a subject in need thereof, comprising administering an effective amount of an inhibitor of TREM2, wherein the inhibitor is a means for binding to TREM2, and wherein the TREM2 to which the inhibitor binds comprises the sequence shown in SEQ ID NO: 15.

[0295] In one aspect, the application provides a method of contacting unstimulated bone marrow cells with an anti-TREM2 antibody, such as a human antibody, resulting in the abrogation of the unstimulated bone marrow cells.

[0296] In another aspect, the application provides a method of contacting unstimulated bone marrow cells with an anti-TREM2 mouse antibody, resulting in the abrogation of the unstimulated bone marrow cells.

[0297] In some embodiments, the non-stimulatory cells are one or more of DC1 cells and TAM cells.

[0298] In some embodiments, the present application provides a method of invalidating non-stimulated bone marrow cells, comprising contacting the non-stimulated bone marrow cells with a TREM2 antibody, thereby killing the non-stimulated bone marrow cells. Invalidation refers to rendering the cells partially or completely non-functional. In some embodiments, invalidating the non-stimulated bone marrow cells results in inducing growth arrest in the cells. In some embodiments, invalidating the non-stimulated bone marrow cells results in apoptosis in the cells. In some embodiments, invalidating the non-stimulated bone marrow cells results in lysis of the cells, for example, by complement-dependent cytotoxicity (CDC) or antibody-dependent cellular cytotoxicity (ADCC). In some embodiments, invalidating the non-stimulated bone marrow cells results in necrosis in the cells. In some embodiments, invalidating the non-stimulated bone marrow cells results in inducing growth arrest in the cells. In some embodiments, invalidating the non-stimulated bone marrow cells results in inactivating the cells. In some embodiments, invalidating the non-stimulated bone marrow cells results in neutralizing the activity of the TREM2 protein in the cells. In some embodiments, invalidating the non-stimulated bone marrow cells results in a decrease in proliferation of the cells. In some embodiments, invalidating the non-stimulated bone marrow cells results in differentiation of the cells. In some embodiments, the nullification of non-stimulatory bone marrow cells results in a decrease in the ability of the cells to act as inhibitory antigen presenting cells or an increase in the ability of the cells to act as activating antigen presenting cells. In some embodiments, the nullification of non-stimulatory bone marrow cells results in the mislocalization of cells in tumor tissue or tumor microenvironment (TME). In some embodiments, the nullification of non-stimulatory bone marrow cells results in a change in the spatial organization of cells in tumor tissue or tumor microenvironment. In some embodiments, the nullification of non-stimulatory bone marrow cells results in a change in the temporal expression of cells in tumor tissue or TME. In some embodiments, the method further comprises removing non-stimulatory bone marrow cells.

[0299] In any and all aspects of the neutralization of unstimulated bone marrow cells described herein, any increase or decrease or change in aspect of the property(ies) or function(ies) is as compared to cells not contacted with the anti-TREM2 antibody.

[0300] In another aspect, the application provides a method of contacting unstimulated bone marrow cells with an anti-TREM2 antibody, thereby resulting in modulation of the function of the unstimulated bone marrow cells. The modulation can be any one or more of the following. In some embodiments, the unstimulated cells are one or more of DC1 cells, TAM1 cells, and TAM2 cells. In some embodiments, the modulation of the function results in the abrogation of the unstimulated bone marrow cells. In some embodiments, the modulation of the function of the unstimulated bone marrow cells results in an increase in the ability of the cells to stimulate both natural and activated CD8+ T cells, for example, by increasing the ability of the unstimulated cells to cross-present antigens on MHCI molecules to naive CD8+ T cells. In some embodiments, the modulation increases the T cell stimulatory function of the unstimulated bone marrow cells, including, for example, the ability of the cells to induce T cell receptor (TCR) signaling, T cell proliferation, or T cell cytokine production. In one embodiment, the survival of the unstimulated cells is decreased or the proliferation of the unstimulated cells is decreased. In one embodiment, the ratio of stimulated bone marrow cells to unstimulated bone marrow cells is increased.

[0301] In any and all aspects of the reduction in function of unstimulated bone marrow cells described herein, any increase or decrease or change in aspect of the property(ies) or function(ies) is as compared to cells not contacted with an anti-TREM2 antibody.

[0302] In some embodiments, the present application provides a method of killing (also referred to as inducing cell death) unstimulated bone marrow cells, comprising contacting unstimulated bone marrow cells with an anti-TREM2 antibody, thereby killing the unstimulated bone marrow cells. In some embodiments, killing is increased compared to unstimulated bone marrow cells not contacted with the anti-TREM2 antibody. In some embodiments, the contacting induces apoptosis in the unstimulated bone marrow cells. In some embodiments, the contacting induces apoptosis in the unstimulated bone marrow cells. In some embodiments, the unstimulated bone marrow cells are in a population of immune cells that includes unstimulated bone marrow cells and stimulated bone marrow cells. In some embodiments, the method further comprises removing the unstimulated myeloid cells. In some embodiments, 10%-80% of the cells are killed. In some embodiments, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, or 80% of the cells are killed.

[0303] In some embodiments, the present application provides a method of increasing the ratio of stimulated bone marrow cells to unstimulated bone marrow cells in a population of immune cells including stimulated and unstimulated bone marrow cells, comprising contacting the population of immune cells with an anti-TREM2 antibody. In some embodiments, the ratio is increased compared to a population of cells not contacted with the anti-TREM2 antibody. In some embodiments, the ratio of DC2 cells to DC1 cells is increased. In some embodiments, the ratio of DC2 cells to TAM1 cells is increased. In some embodiments, the ratio of DC2 cells to TAM2 cells is increased. In some embodiments, the ratio of DC2 cells to TAM1+TAM2 cells is increased. In some embodiments, the ratio of DC2 cells to TAM1+DC1 cells is increased. In some embodiments, the ratio of DC2 cells to DC1+TAM2 cells is increased. In some embodiments, the ratio is increased by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%.

[0304] In some embodiments, the ratio of stimulated bone marrow cells to unstimulated bone marrow cells before contact ranges from 0.001:1 to 0.1:1. In some embodiments, the ratio of stimulated bone marrow cells to unstimulated bone marrow cells after contact ranges from 0.1:1 to 100:1.

[0305] In some embodiments, the number of unstimulated bone marrow cells is decreased. In some embodiments, the stimulated bone marrow cells are DC2 cells. In some embodiments, the unstimulated bone marrow cells die, for example, by necrosis or apoptosis. In some embodiments, the unstimulated bone marrow cells are induced to undergo growth arrest. In some embodiments, the unstimulated bone marrow cells no longer proliferate. In some embodiments, the spatial localization of unstimulated bone marrow cells is altered, with the proportion increasing in certain regions of the TME. In some embodiments, the temporal expression of unstimulated bone marrow cells is altered, with the proportion increasing during certain times.

[0306] In some embodiments, the contacting is in vitro. In some embodiments, the contacting is in vivo. In some particular embodiments, the contacting is in vivo in a human. In some embodiments, the contacting is by administering an anti-TREM2 antibody. In some embodiments, the fibrotic disease is not cancer.

[0307] In some embodiments, the individual (such as a human) receiving the antibody has a fibrotic disease, e.g., a liver disease. In some embodiments, the liver disease is fibrosis, nonalcoholic fatty liver disease (NAFLD), nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), cirrhosis, or liver cancer. In some embodiments, the liver disease is a fatty liver disease, such as liver disease resulting from hepatitis, fatty liver disease resulting from obesity, fatty liver disease resulting from diabetes, fatty liver disease resulting from insulin resistance, fatty liver disease resulting from hypertriglyceridemia, abetalipoproteinemia, glycogen storage disease, Weber-Christian disease, Wolman disease, acute fatty liver of pregnancy, and lipoatrophy.

[0308] NASH is characterized as the presence of inflammation, hepatocellular injury, and various degrees of fibrosis. The underlying mechanisms involved in the pathogenesis of NASH are not fully understood. It has been shown that liver macrophages coordinate both the progression and repair of NASH. The activation of liver macrophages during NASH progression is a dynamic procedure that depends on various stimuli, such as cytokines, lipid metabolites, and other signal molecules. Together with surrounding cells, liver macrophages can trigger inflammatory responses, fibrogenesis, vascular remodeling, and so on. Intercellular signaling between liver macrophages and surrounding cells is known to be involved in NASH development. Liver macrophages are an attractive target for NASH treatment.

[0309] TREM2 expression was strongly associated with the severity of NASH. The more diseased the liver, the more cells produced TREM2. Macrophages were present in substantially higher proportions in diseased livers and produced TREM2 more actively. A NASH-specific macrophage population marked by high expression TREM2, termed NASH-associated macrophages (NAM), was observed in both mouse and human NASH livers. A pathogenic subpopulation of TREM2+CD9+ macrophages, named scar-associated macrophages (SAMacs), was also identified in the fibrotic niche of human livers with NASH. The expansion of SAMacs was positively correlated with the extent of NASH-induced liver fibrosis.

[0310] In some embodiments, a method of treating a fibrotic disease in an individual, comprising administering to the individual a composition comprising an effective amount of an anti-TREM2 antibody.

[0311] In some embodiments, treating a fibrotic disease in a human or treatment includes one or more of: (1) preventing or reducing the risk of developing a fibrotic disease, i.e., preventing the development of clinical symptoms of a fibrotic disease in a subject who may be predisposed to a fibrotic disease but has not yet experienced or exhibited symptoms of the fibrotic disease (i.e., prevention); (2) inhibiting the fibrotic disease, i.e., preventing or reducing the development of the fibrotic disease or its clinical symptoms; and / or (3) reducing the fibrotic disease, i.e., causing regression, reversal, or amelioration of the fibrotic disease or reducing the number, frequency, duration, or severity of its clinical symptoms.

[0312] In some embodiments, treating or treating a liver disease such as NAFLD or NASH in a human includes one or more of: (1) preventing or reducing the risk of developing NAFLD or NASH, i.e., not allowing clinical symptoms of NAFLD or NASH to develop in a subject who may be predisposed to NAFLD or NASH but has not yet experienced or exhibited symptoms of NAFLD or NASH (i.e., prevention); (2) inhibiting NAFLD or NASH, i.e., preventing or reducing the development of NAFLD or NASH or its clinical symptoms; and (3) alleviating NAFLD or NASH, i.e., causing regression, reversal, or improvement of NAFLD or NASH, or reducing the number, frequency, duration, or severity of its clinical symptoms.

[0313] The therapeutically effective amount for a particular subject varies according to the health and physical condition of the subject to be treated, the degree of NAFLD or NASH, the evaluation of medical conditions, and other relevant factors.It is expected that the therapeutically effective amount will fall within a relatively broad range that can be determined through routine testing.Those skilled in the art of treating fibrotic diseases will be able to ascertain the therapeutically effective amount for a particular stage of the disease and achieve the therapeutically effective amount without undue experimentation, relying on their personal knowledge and the disclosure of this application.

[0314] In another aspect, the present invention provides a method for treating an immune-related condition in an individual, comprising administering to the individual a composition comprising an effective amount of an anti-TREM2 antibody. In another aspect, the present invention provides a method for enhancing an immune response in an individual, comprising administering to the individual a composition comprising an effective amount of an anti-TREM2 antibody. In some embodiments, these methods are further provided in combination with other combination therapies, such as PDL blockade therapy, anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-PD-L2 antibodies, CTLA4 blockade therapy, anti-CTLA-4 antibodies, generalized checkpoint blockade therapy in which inhibitory molecules on T cells are blocked, adoptive T cell therapy, CAR T cell therapy, dendritic cell or other cell therapy, as well as conventional chemotherapy.

[0315] In some embodiments, the method further comprises determining the expression level of the TREM2 protein in a biological sample from the individual. In some embodiments, the biological sample includes, but is not limited to, a body fluid, a tissue sample, an organ sample, urine, feces, blood, saliva, CSF, and any combination thereof. In some embodiments, the biological sample is derived from a tissue. In some embodiments, the expression level comprises an mRNA expression level of an mRNA encoding the TREM2 protein. In some embodiments, the expression level of the TREM2 protein comprises a protein expression level of an NSM. In some embodiments, the expression level of the TREM2 protein is detected in the sample using a method selected from the group consisting of FACS, Western blot, ELISA, immunoprecipitation, immunohistochemistry, immunofluorescence, radioimmunoassay, dot blotting, immunodetection methods, HPLC, surface plasmon resonance, optical spectroscopy, mass spectrometry, HPLC, qPCR, RT-qPCR, multiplex qPCR or RT-qPCR, RNA-seq, microarray analysis, SAGE, MassARRAY technology, and FISH, and combinations thereof.

[0316] In another aspect, the application provides a method for determining the presence or absence of unstimulated bone marrow cells generally, or for determining the presence or absence of specific unstimulated bone marrow cells (e.g., DC1 cells, TAM1 cells, and / or TAM2 cells), comprising contacting a population of cells including unstimulated bone marrow cells with an anti-TREM2 antibody and quantifying the number of unstimulated bone marrow cells. In another aspect, the application provides a method for determining the presence or absence of unstimulated bone marrow cells, comprising contacting a population of immune cells including unstimulated and stimulatory bone marrow cells with an anti-TREM2 antibody, detecting a complex or moiety indicative of binding of the antibody to the cells, and optionally quantifying the number of unstimulated bone marrow cells in the population. In another aspect, a method is provided for determining the relative ratio of unstimulated to stimulated bone marrow cells, comprising contacting a population of immune cells comprising unstimulated and stimulated bone marrow cells with an anti-TREM2 antibody, quantifying the number of stimulated and unstimulated bone marrow cells, and determining the relative ratio of unstimulated to stimulated bone marrow cells.

[0317] In the embodiments described herein for detection and / or quantification, the anti-TREM2 antibody binds to the TREM2 protein but does not necessarily affect a biological response such as ADCC, although it may affect a biological response.

[0318] In another aspect, the present invention provides a method for identifying an individual who may respond to immunotherapy (e.g., with an anti-TREM2 antibody) for the treatment of an immune-related condition, comprising detecting an expression level of TREM2 protein in a biological sample from the individual, and determining whether the individual may respond to immunotherapy based on the expression level of TREM2 protein, where an elevated level of TREM2 protein in the individual compared to healthy individuals indicates that the individual may respond to immunotherapy. In some embodiments, these methods may also be used to diagnose an immune-related condition in an individual, based on the expression level of TREM2 protein, where an elevated level of TREM2 protein in the individual compared to healthy individuals indicates that the individual is suffering from a fibrotic disease. In some embodiments, the expression level comprises an mRNA expression level of an mRNA encoding the TREM2 protein. In other embodiments, the expression level of the TREM2 protein comprises a protein expression level of the TREM2 protein. In some embodiments, the expression level of TREM2 protein is detected in the sample using a method selected from the group consisting of FACS, Western blot, ELISA, immunoprecipitation, immunohistochemistry, immunofluorescence, radioimmunoassay, dot blotting, immunodetection methods, HPLC, surface plasmon resonance, optical spectroscopy, mass spectrometry, HPLC, qPCR, RT-qPCR, multiplex qPCR or RT-qPCR, RNA-seq, microarray analysis, SAGE, MassARRAY technology, and FISH, and combinations thereof. In these embodiments, the anti-TREM2 antibody binds to the TREM2 protein but does not necessarily affect a biological response such as ADCC. In some embodiments, the biological sample is derived from a tissue. In some embodiments, the biological sample includes, but is not limited to, a body fluid, a tissue sample, an organ sample, urine, feces, blood, saliva, CSF, and any combination thereof.

[0319] Also disclosed herein is a method for enhancing the immune response of a subject or enhancing the effectiveness of immunotherapy treatment.Generally, treatment that increases the abundance of SDC improves the outcome of a subject, such as recurrence-free survival time, and enhances the effectiveness of immunotherapy treatment.Treatment can increase the relative or absolute abundance of SDC cells in a subject.Treatment can decrease the relative or absolute abundance of NSM cells in a subject.

[0320] An exemplary method of the general therapeutic strategy involves increasing the number of SDCs by systemic introduction of Flt3L. Another method is to treat the subject's autologous bone marrow or blood cells with Flt3L while simultaneously blocking CSF1. Expression of SDC transcription factors such as IRF8, Mycl1 or BATF3 or ZBTB46 in bone marrow or blood progenitor cell populations, for example by retrovirus, may also be used to promote SDC development. Another strategy of treatment involves systematically removing NSM cells while selectively restricting SDCs. This can produce an overall favorable change in the ratio of these populations. Removal of NSM cells can be achieved by any means, including administration of antibodies against the TREM2 surface protein.

[0321] In some embodiments, the SDC enhancement therapy is applied as a therapeutic treatment to better enable the subject's innate immune system to control or eradicate the disease. In another embodiment, the SDC enhancement therapy of the present invention is applied in combination with a therapeutic treatment, such as an immunotherapy treatment (such application is before, simultaneously with, or after the immunotherapy treatment), and the SDC enhancement therapy functions as a supplementary or adjuvant therapy to increase the effectiveness of the therapeutic treatment.

[0322] Method of administration In some embodiments, the methods provided herein are useful for treating an immune-related condition in an individual. In one embodiment, the individual is a human and the antibody is a TREM2 antibody. In another embodiment, the individual is a mouse and the antibody is a TREM2 antibody.

[0323] Any fibrotic disease may be treated with the antibody provided herein.The disease may be fibrosis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), cirrhosis, or liver cancer as known in the medical field.In some embodiments, the immune-related condition may be a fibrotic disease, such as liver disease.

[0324] In some embodiments, the immune-related condition is an immune-related condition associated with expression of TREM2 protein on unstimulated bone marrow cells (in humans) or expression of a homologue of TREM2 protein in a non-human species. In some embodiments, the immune-related condition is an immune-related condition associated with overexpression of TREM2 protein on unstimulated bone marrow cells compared to stimulated bone marrow cells. In some embodiments, overexpression of TREM2 mRNA or TREM2 protein is approximately at least 2-fold, 5-fold, 10-fold, 25-fold, 50-fold, or 100-fold higher compared to stimulated bone marrow cells.

[0325] In some embodiments, the treatment enhances an immune response in the subject. In some embodiments, the enhanced immune response is an adaptive immune response. In some embodiments, the enhanced immune response is an innate immune response.

[0326] In some embodiments, the antibody is administered intravenously, intramuscularly, subcutaneously, topically, orally, transdermally, intraperitoneally, intraorbitally, by implantation, by inhalation, intrathecally, intracerebroventricularly, or intranasally. An effective amount of an anti-TREM2 antibody may be administered for the treatment of a disease. The appropriate dosage of an anti-TREM2 antibody may be determined based on the type of disease being treated, the type of anti-TREM2 antibody, the severity and course of the disease, the individual's clinical condition, the individual's clinical history and response to treatment, and the discretion of the attending physician.

[0327] Combination therapy In some embodiments, the antibodies provided herein are administered with at least one additional therapeutic agent. Any suitable additional therapeutic agent may be administered with the antibodies provided herein.

[0328] For the treatment of fibrotic diseases, the anti-TREM2 antibodies may be combined with one or more additional therapeutic agents.

[0329] Kits and Articles of Manufacture The present application provides a kit comprising any one or more of the antibody compositions described herein. In some embodiments, the kit further comprises a component selected from any of the following: a secondary antibody, a reagent for immunohistochemistry analysis, a pharma- ceutically acceptable excipient, and an instruction manual, and any combination thereof. In one particular embodiment, the kit comprises a pharmaceutical composition comprising any one or more of the antibody compositions described herein together with one or more pharma-ceutically acceptable excipients.

[0330] The present application also provides an article of manufacture comprising any one of the antibody compositions or kits described herein. An example of an article of manufacture is a vial (including a sealed vial). EXAMPLES

[0331] Below are examples of specific embodiments for carrying out the present invention. These examples are presented for illustrative purposes only and are not intended to limit the scope of the present invention in any way. Efforts have been made to ensure accuracy with respect to the numerical values ​​used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should, of course, be allowed for.

[0332] The practice of the present invention will employ, unless otherwise indicated, conventional methods of protein chemistry, biochemistry, recombinant DNA technology, and pharmacology, within the skill of the art. Such techniques are explained fully in the literature, see, for example, TECreighton, Proteins: Structures and Molecular Properties (WH Freeman and Company, 1993); A. L. Lehninger, Biochemistry (Worth Publishers, Inc., current addition); Sambrook, et al., Molecular Cloning: A Laboratory Manual (2nd Edition, 1989); Methods In Enzymology (S. Colowick and N. Kaplan eds., Academic Press, Inc.); Remington's Pharmaceutical Sciences, 18th Edition (Easton, Pennsylvania: Mack Publishing Company, 1990); Carey and Sundberg Advanced Organic Chemistry 3rd Edition (Easton, Pennsylvania: Mack Publishing Company, 1992); rd Ed. (Plenum Press) Vols A and B (1992).

[0333] Example 1: Anti-TREM2 antibodies. Anti-TREM2 antibodies were obtained as disclosed in USPN 10,836,828, which is incorporated herein by reference for all purposes. Table 1A shows the VL, VH, and full heavy and light chain sequences of humanized embodiments of anti-TREM2 antibodies. 37017 is the parent humanized clone from which other humanized embodiments were generated via additional mutations. Table 1B shows the CDR sequences (see Dr. Andrew CRMartin's website at www.bioinf.org.uk / abs / for a table comparing CDR definitions).

[0334] [Table 1A] TIFF2024542618000008.tif219165TIFF2024542618000009.tif95165

[0335] [Table 1B]

[0336] TIFF2024542618000011.tif231165

[0337] In the VL domain, in the CDR, Asn28, Asn31, Asn32 and Asn53 have low potential for deamidation based on sequence and conformation. Asn93 has low to moderate potential for deamidation and may show low level of this post-translational modification. In the VH domain, Asn31 has low potential for deamidation based on sequence and conformation. In the CDR-H2, Asn53 has moderate potential for deamidation and Asn53 can be modified to Gln, Ser or Ala to prevent post-translational modification and maintain binding experimentally. In the CDR-H3, Trp100 may be solvent exposed and may have potential for oxidation, especially under stress conditions.

[0338] In-solution endoproteinase digestion In-solution endoproteinase digestion of monoclonal antibodies (mAbs) was performed for mAb sequencing analysis. 50 μg of antibody was reduced with DTT, alkylated with iodoacetamide, acetone precipitated, and reconstituted in water at a concentration of 1 μg / μL. In-solution digestion of antibody samples was performed according to the manufacturer's instructions using five individual enzyme digestions: Asp-N, chymotrypsin, elastase, trypsin, and pepsin. Samples were then lyophilized, resuspended in 0.1% TFA, and purified using a C18 Zip-Tip. Samples were then dried by high vacuum centrifugation and kept frozen until mass spectrometry.

[0339] mass spectrometry Intact mass measurement The mAb samples were denatured, reduced, and acidified. Proteins were then analyzed using an Agilent 1100 HPLC coupled to a Waters QToF Ultima Global mass spectrometer (LC-ESI-TOF MS). Appropriate LC-MS spectra were processed (combined, subtracted, smoothed, and deconvoluted) using Waters MassLynx 4.1 software.

[0340] LC-MS / MS analysis Purified peptides were resuspended in 0.1% formic acid and half of each digest was analyzed on an Orbitrap analyzer (Q-Exactive, Thermo Fisher Scientific) equipped with a nanospray source and an EASY-nLC 1000 system (Thermo Fisher Scientific). Peptides were loaded onto a 50 cm (75 μm internal diameter) EASY-Spray column packed with PepMap® RSLC 2 μm C18 resin (Thermo Fisher Scientific) at 800 Bar pressure. Peptides were eluted at a rate of 250 nl / min over 60 min using a gradient set as 0% to 30% acetonitrile in 0.1% formic acid. Peptides were introduced into the Q-Exactive mass spectrometer (Thermo Fisher Scientific) by a nanoelectrospray ion source. The instrument method consisted of one MS full scan (400-1600 m / z) on an Orbitrap mass analyzer with an automatic gain control (AGC) target of 1E6, a maximum ion injection time of 120 ms, and a resolution of 70000, followed by 10 data-dependent MS / MS scans with a resolution of 17500, an AGC target of 5E5, and a maximum ion time of 100 ms, and one microscan. The intensity threshold to trigger the MS / MS scan was set to an underfill ratio of 1.0%. Fragmentation was performed in an HCD collision cell with a normalized collision energy set to 30. Dynamic exclusion was applied using a setting of 8 s.

[0341] Table 2 summarizes the biophysical properties of the humanized clones. The molecular weights and extinction coefficients are estimated for the sum of the contributing protein chains in the quaternary structure. By default, the calculation assumes equal monomer contributions from each chain. The extinction coefficients are M -1 cm -1 It has units of predicted absorbance at 280 nm per mole of protein. Potential post-translational modifications such as glycosylation, phosphorylation, and proteolysis are not taken into account in the estimation of molecular weight or extinction coefficient.

[0342] [Table 2]

[0343] Example 2: Production and characterization of anti-TREM2 antibodies Antibody production and characterization Standard protein expression vectors were transfected into HEK293 using standard methods, after which the cells were grown for 7 days and harvested. In addition to HEK293, antibodies were also produced in 293 cells that were deficient in mammalian a1,6-fucosyltransferase (FUT8) by CRISPR / Cas9 editing (Alexander Weiss, University of Toronto). Supernatant pH was adjusted with 1M Hepes pH 7.4, and sodium azide was added to prevent microbial growth. Proteins were captured using KanCap A resin, and after washing with PBS and PBS containing 1M sodium chloride, antibodies were eluted with 50 mM citrate pH 3.5, 100 mM NaCL. Immediately after elution, the solution was neutralized with 1M Tris (pH 8) containing 0.5M arginine. Biophysical characterization was performed on proteins buffer exchanged into PBS using standard techniques. Proteins were quantified by OD280, and amounts and concentrations were determined using calculated extinction coefficients. Purity and approximate molecular mass were determined using reducing and non-reducing SDS-PAGE (Biorad criterion Tris / glycine / SDS, 4-20%) or a Perkin Elmer GXII capillary electrophoresis system. Aggregation state was determined by HPLC using a Sepax Zenix-C SEC-300, 3um, 300Å, 4.6×150mm size exclusion column and PBS running buffer with detection at 280nm.

[0344] Antibody affinity measurement using surface plasmon resonance (SPR) Binding kinetics were determined by surface plasmon resonance using a Biacore T200 (GE Healthcare, UK) with human TREM2 His (Sino Biological, Beijing, PRChina) or human captured on a Series S CM5 chip by anti-His capture, or TREM2 human IgG1 Fc fusion protein (in-house SEC purified to >95% purity) directly immobilized on the chip by amine coupling. Serial dilutions of the indicated antibodies were injected at 30 μl / min for 2 min. PBS or system buffer was then injected at 30 μl / min for 400 s to observe dissociation. Binding responses were corrected by subtracting the response on a blank flow cell. For kinetic analysis, k on and k off A 1:1 Langmuir model of global fitting of the values ​​was used. d The value is k on and k off was determined from the ratio of

[0345] [Table 3]

[0346] [Table 4]

[0347] At low ligand density (RL=500 RU), the binding kinetics of PI37017 to human TREM2-Fc did not yield a good fit.

[0348] Example 3: Cell Binding of Anti-TREM2 Antibodies Cell binding (EC50 measurement): 100,000–500,000 Expi 293 parental cells or Expi 293 overexpressing human or mouse TREM2 were plated in 96-well plates and dead cells were stained with Zombie Near Infrared (Biolegend). Titrations of the indicated unconjugated antibodies were incubated with these cells ranging from 0 μg / ml to 10 μg / ml at a 1:3 dilution range over 8–10 points. Depending on their isotype (hIgG1 or mIgG2a), these primary unconjugated antibodies were detected with Alexa Fluor 647-conjugated anti-human Fc or anti-mouse Fc secondary antibodies (Jackson Immunoresearch). Alexa Fluor 647 signal was measured by flow cytometry (BD Fortessa X-14, BD Biosciences). EC50 values ​​were calculated by curve fitting signals generated from antibody binding to overexpressing cells over background fluorescence generated from parental HEK293 cells in Graphpad Prism (Graphpad Software).

[0349] [Table 5]

[0350] Example 4: No obvious toxicity associated with anti-TREM2 therapy Materials and Methods Tissues (lung, liver, brain, kidney, and heart) from mice treated with 7012 antibody (which has the CDR sequences of PI37012 and is murine in mouse IgG2a format) were stored in 10% neutral buffered formalin for at least 24 hours, routinely processed for histology, cut at 5-6 μm, and sections stained with hematoxylin and eosin. Stained slides were examined using a low-power (40-100x) light microscope and images were obtained by HistoWiz. CD68-positive cells were detected using an anti-CD68 antibody (AbD Serotec) and quantified in 8-9 fields of 40x sections using a light microscope.

[0351] result Gross morphological analysis by H&E staining of mouse tissues (lung, liver, heart, kidney, and brain) after treatment revealed no morphological changes in PI-7012, afuc-PI-7012, and anti-PD-1 combination treated mice compared to isotype control treated mice (Figure 1 shows the staining of lung tissue).

[0352] In addition to H&E staining, tissues were also stained for macrophages using anti-CD68. The intracellular marker CD68 is widely used in the literature as a reliable cytochemical marker for immunostaining monocytes / macrophages in inflamed tissues and tumors. No discernible changes in the number of CD68+ macrophages were observed in the lung (Figure 2A) or in the other tissues analyzed in any of the treatment groups compared to controls (Figure 2B), indicating that anti-TREM2-mediated depletion occurred specifically in the TME.

[0353] Example 5: Restricted expression of TREM2 in healthy mouse tissues Materials and Methods All animal studies were approved by the Murigenics Animal Studies Committee. em2AdiujC57BL / 6J mice (hereafter referred to as TREM2KO) and control C57BL / 6J mice were from The Jackson Laboratory. Whole lungs, spleens, and bones were harvested and immediately processed for flow cytometry. Blood was collected by cardiac puncture in parallel. Tissues were processed into single cell suspensions using the Miltenyi MACS tissue dissociation kit. Red blood cells were lysed using 1x Red Blood Cell Lysis Buffer (Biolegend). Before processing for cell surface staining, cells were stained with Fixable Viability Dye (ThermoFisher Scientific). Anti-mouse immunophenotypic antibodies were diluted in FACS buffer (2% FBS, 2mM EDTA, 1x PBS) with Fc block and stained for 30 min on ice. After staining, cells were washed twice with FACS buffer and then fixed in 2% paraformaldehyde in PBS for 15 min. All data were collected on an LSR Fortessa flow cytometer (BD) or an Attune flow cytometer (Thermo Fisher) and analyzed using FlowJo software. TREM2KO cell staining is shown in shaded plots and wild-type cell staining is shown in open plots.

[0354] result TREM2 is expressed on activated macrophages, immature dendritic cells, osteoclasts, and microglia 2、3 Cells expressing high levels of TREM2 are thought to be involved in immune surveillance, cell-cell interactions, tissue debris clearance, and potentially resolution of inflammatory responses. 4 Lack of TREM2 expression on these cells by genetic knockdown or knockout impairs their ability to phagocytose cellular debris and increases production of regulatory cytokines. 5 In a physiological setting, there is very low or no detectable expression of TREM2 in peripheral blood, spleen, liver, or lungs, as seen in the FACS plots (Figure 3). However, when macrophages present in the lungs or liver are isolated and stained for TREM2 as a pure cell population, expression of TREM2 becomes detectable.

[0355] Example 6: TREM2 is predominantly expressed on mouse TAMs. Materials and Methods Tumor tissue was processed to isolate single cell suspensions by standard methods. Briefly, tumors were finely pulverized with razor blades and digested in RPMI-1640 medium containing enzymes from the Miltenyi MACS dissociation kit. Tumors were treated with GentleMAC according to the manufacturer's recommendations and incubated at 37°C for approximately 40 minutes. The digestion mixture was quenched with PBS containing 2 mM EDTA and 2% fetal bovine serum. The single cell suspension was then passed through a 70 μm filter, and the cells were then rinsed with FACS buffer. After centrifugation, the cell pellet was resuspended in FACS buffer and stained with an antibody cocktail to identify tumor-associated macrophages and other immune cell populations. 6 TREM2KO cell staining is shown in the shaded plots and wild-type cell staining is shown in the open plots.

[0356] result T cells, B cells, NK cells, and other non-myeloid cell populations, as well as CD45-negative cells, do not express detectable TREM2 expression on the cell surface. However, myeloid cell subsets, including tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs), express TREM2 to varying degrees on the cell surface. Among the cell types that are TREM2 positive in the tumor microenvironment, the receptor expression density on TAMs was significantly higher than other cell types, regardless of tumor origin (CT26 and MC38 shown in Figure 4).

[0357] Example 7: Restricted TREM2 expression in human peripheral blood leukocytes Materials and Methods Peripheral blood mononuclear cells (PBMCs) obtained from normal human volunteers and negatively selected CD14+ monocytes were provided by AllCells Inc. CD14+ monocytes were differentiated in vitro using standard protocols. 5 CD14 +Monocytes were cultured in complete medium consisting of RPMI-1640 medium supplemented with 2 mM L-glutamine, 100 μg / ml streptomycin, 100 U / ml penicillin, and 10% heat-inactivated FBS. To induce differentiation into macrophages, 50 ng / mL M-CSF was added to the medium. The medium was replenished every 2–3 days. After 7 days, macrophages were collected by pipetting and adherent cells were collected by subsequent trypsinization. Cells were then centrifuged and resuspended in RPMI-1640 supplemented with antibiotics, 2% FBS, and recombinant human IFN-g, and 100 ng / mL LPS. These macrophages were surface stained in parallel with PBMCs using a standard myeloid cocktail to assess cell surface staining of TREM2 in cell subsets. Cells stained with control mAb are shown in the shaded plot. Cells stained with anti-TREM2 mAb are shown in white plots.

[0358] result As can be seen in Figure 5, ex vivo differentiated macrophages display a significantly higher cell surface receptor density for TREM2 compared to any PBMC-based cell type evaluated. Similar to observations reported in the literature, monocytes and some neutrophils express lower levels of TREM2.

[0359] Example 8: TREM2 is expressed primarily on human TAMs. Materials and Methods Human tumor tissues were obtained from the Cooperative Human Tissue Network (CHTN). Fresh human tumor tissues were dissociated into single cell suspensions using the Miltenyi MACS dissociation kit and gentleMACS protocol. Single cell suspensions of human tumor tissues were surface stained using a pre-validated multicolor FACS panel. All data were collected on an LSR Fortessa flow cytometer (BD) or an Attune flow cytometer (Thermo Fisher) and analyzed using FlowJo software. Numbers indicate the staining index for each population, defined as anti-TREM2 staining minus isotype control staining.

[0360] result Within the tumor microenvironment, TREM2 expression is differentially expressed at high levels on TAMs compared to other cells (Figure 6), making it a translationally relevant marker for TAMs. Representative histograms of TREM2 antibody (white) or isotype control (shaded) staining in various cell populations in mucinous adenocarcinoma are shown. Collectively, this data supports the hypothesis that TREM2-targeting agents aid in specific TAM depletion with relatively low or no collateral effects on peripheral cells or other tissue-resident immune subsets.

[0361] Example 9: ADCC induction by anti-TREM2 antibody Materials and Methods HEK-293 cells (DAP12) overexpressing human TREM2 fused to TYROBP were used as target cells. Primary human NK cells, sorted for high purity and assessed to express CD16, were used as effector cells after being adapted to culture in 100 ng / mL recombinant IL-2-containing medium. Target cells were first incubated with the indicated concentrations of antibody (PI37012 anti-TREM2 mAb or isotype control) for 20 min in U-bottom 96-well plates. After 20 min, effector cells were added to the culture plate to obtain an effector-to-target ratio of 1:5 (10,000 target cells:50,000 NK cells per well). Assay plates were incubated at 37 °C for 4–6 h, followed by testing of supernatants for lactate dehydrogenase (LDH) release as a measure of target cytotoxicity using a commercial kit according to the supplier's (Promega) instructions.

[0362] result As can be seen in Figure 7, relative cytotoxicity, as measured by LDH release, was increased in target cells incubated with anti-TREM2 mAb (black bars, shown on the left) compared to the isotype control (white bars, shown on the right) across all mAb concentrations tested. These results indicate that anti-TREM2 antibodies induce ADCC in target cells expressing TREM2.

[0363] Example 10: Fc domain defucosylation enhances the induction of ADCC Materials and Methods Green fluorescent protein (GFP)-labeled Expi293 cells stably expressing mouse TREM2 or GFP alone were cultured at 4 °C in a 37 °C culture medium at 8% CO. 2 The cells were maintained in Expi293 medium (Gibco) at 37°C and 40°C. The FcγR-dependent activity of mouse anti-TREM2 antibodies was evaluated using a mouse FcγRIV-expressing Jurkat / NFAT-luciferase reporter cell line (Promega). Target cells were cultured at 1 × 10 per mL. 6 Cells were resuspended in assay medium (RPMI 1640 containing 10% fetal bovine serum and 55 μM 2-mercaptoethanol) at 1000 cells and 25 μL of cell suspension containing 25,000 cells were plated into white-walled flat-bottom 96-well assay plates (Corning). Dose titrations of monoclonal antibodies (including defucosylated PI-7012 anti-TREM2, PI-7012 anti-TREM2, and PI-7012 anti-TREM2 Fc-silenced antibodies) were prepared at 3x concentration in assay medium and 25 μL of antibody was added to the cell suspension. After antibody addition, 25 μL of effector cell suspension containing 75,000 cells was added to the well to give an effector:target cell ratio of 3:1. Cells were incubated at 4°C for 24 h at 37°C for 30 min at 5% CO. 2 After approximately 5.5 h of co-culture in an incubator set at 37 °C, 75 μL of Bio-Glo luciferase assay reagent (Promega) was added to each well and the assay plate was further incubated for 15 min in the dark. Luminescence (RLU) was assessed on a Tecan Spark plate reader and used as a surrogate measure of ADCC activity.

[0364] result As can be seen in Figure 8, defucosylated anti-TREM2 mAb (indicated by the circular data points) caused the greatest induction of ADCC as measured by NFAT reporter activity. Non-defucosylated anti-TREM2 antibodies also induced ADCC, albeit at reduced relative levels. In contrast, no measurable induction of ADCC was observed in target cells treated with Fc-silenced anti-TREM2 mAb.

[0365] Example 11: Anti-TREM2 antibody treatment of liver fibrosis Previous studies in rodents have highlighted macrophage subpopulations that orchestrate both the progression and regression of liver fibrosis, with local proliferation playing a key role in the expansion of macrophages at sites of fibrosis in rodent models. Duffield JS,et al.J Clin Invest.2005;115:56-65., Ramachandran P,et al.Proc Natl Acad Sci.2012;109:E3186-E3195., Karlmark KR,et al.Hepatology.2009;50:261-274., Minutti CM,et al.Science(80-.).2017;356:1076-1080.

[0366] Adult male C57BL / 6JCrl mice, 8-10 weeks of age, are purchased from Charles River. Mice are housed under specific pathogen-free conditions. All experimental protocols have been ethically approved. Liver fibrosis is induced with 4 weeks (9 injections) of twice weekly intraperitoneal carbon tetrachloride (CCl4) at a dose of 0.4 μl / g body weight, diluted 1:3 in olive oil, as previously described (Ramachandran P, et al. Proc Natl Acad Sci. 2012;109:E3186-E3195.). Mice are randomly assigned to receive CCl4 or serve as healthy controls.

[0367] Mice are administered antibody treatment after CCl4 administration. Antibodies are either anti-TREM2 or isotype control. Exemplary antibody administration protocols are shown in Table 6 below. PI-7012, Fc-silent PI-7012, and Afuc-PI-7012 (with the CDR sequences of PI37012 and murine in mouse IgG2a format) were generated as described in USPN 10,836,828 (incorporated herein by reference for all purposes).

[0368] [Table 6]

[0369] Liver tissues are harvested at different time points after the final CCl4 injection.

[0370] Administration of an anti-TREM2 antibody results in regression of fibrosis or a slowing of fibrosis progression compared to controls.

[0371] Administration of anti-TREM2 antibodies results in a reduction in the number of TREM2+ macrophages in the scar area compared to controls.

[0372] Administration of anti-TREM2 antibodies results in a reduction in the number of TREM2+ macrophages in cirrhotic liver (e.g., within the fibrotic niche) compared to controls.

[0373] In addition, body weight, liver weight, liver enzymes, survival, hydroxyproline, and / or histopathology show improvements in the anti-TREM2 antibody treated groups compared to controls.

[0374] Example 12: Anti-TREM2 antibody treatment in additional fibrosis models Additional fibrosis models will be tested, including lung, NASH, skin, and kidney.

[0375] lung Pulmonary fibrosis is induced by bleomycin administration (oropharyngeal) as described in Della Latta, V, et al. Pharmacol Res. 2015; 97: 122-130, Izbicki, G, et al. Int J Exp Pathol. 2002; 83: 111-119, and Mouratis, MA, et al. Curr Opin Pul Med. 2011; 17: 355-361, which are incorporated by reference herein for all purposes. Alternatively, pulmonary fibrosis is induced by silica delivered via the oropharyngeal route as described in Barbarin, V, et al. Respir Res. 2005; 6: 112, and Brass, DM, et al. Am J Physiol Lung Cell Mol Physio 2010; 200: L664-L671. Mice are administered bleomycin followed by antibody treatment. Antibodies are either anti-TREM2 or isotype control. Exemplary antibody administration protocols are shown in Table 7 below.

[0376] [Table 7]

[0377] Administration of an anti-TREM2 antibody results in regression of fibrosis or a slowing of fibrosis progression compared to controls.

[0378] Administration of anti-TREM2 antibodies results in a reduction in the number of TREM2+ macrophages in the scar area compared to controls.

[0379] In addition, body weight, normalized lung weight, BAL white blood cell count, BAL cytokine levels, and / or Sircol assays show improvement in the anti-TREM2 antibody treated groups compared to controls.

[0380] NASH Nonalcoholic steatohepatitis (NASH) is induced by feeding a high fat diet for 14 weeks as described in Nakamura, A et al. Int J Mol Sci. 2013;14:21240-21257, Xu, ZJ, et al. Dig Dis Sci. 2010;55:931-940, and Larter, CZ, et al. J Gastroen Hepatol. 2008;23:1635-1648, which are incorporated by reference herein for all purposes.

[0381] Mice are fed a high fat diet followed by antibody treatment. Antibodies are either anti-TREM2 or isotype control. An exemplary antibody dosing protocol is shown in Table 8 below.

[0382] [Table 8]

[0383] Administration of an anti-TREM2 antibody results in regression of fibrosis or a slowing of fibrosis progression compared to controls.

[0384] Administration of anti-TREM2 antibodies results in a reduction in the number of TREM2+ macrophages in the scar area compared to controls.

[0385] In addition, body weight, liver weight, liver enzymes, histology, survival, hydroxyproline, MCP1, collagen, SMA-a, triglycerides, cholesterol, and / or histopathology show improvements in the anti-TREM2 antibody treated groups compared to controls.

[0386] skin Dermal fibrosis is induced by bleomycin administration as described in Yamamoto, T, et al. Exp Dermatol. 2005;14:81-95, Ruzehaji, N, et al. Arthritis Res Ther. 2015;17:145, and Yamamoto, T, et al. J Invest Dermatol. 1999;112:456-462, which are incorporated by reference herein for all purposes.

[0387] Mice are administered bleomycin followed by antibody treatment. Antibodies are either anti-TREM2 or isotype control. An exemplary antibody administration protocol is shown in Table 9 below.

[0388] [Table 9]

[0389] Administration of an anti-TREM2 antibody results in regression of fibrosis or a slowing of fibrosis progression compared to controls.

[0390] Administration of anti-TREM2 antibodies results in a reduction in the number of TREM2+ macrophages in the scar area compared to controls.

[0391] In addition, body weight, histology, and / or hydroxyproline show improvements in the anti-TREM2 antibody treated groups compared to controls.

[0392] kidney Renal fibrosis is induced by ureteral obstruction as described in Chevalier, RL, et al. Kidney Int. 2009;75:1145-1152 and Nogueira, A, et al. In Vivo. 2017;31:1-22, which are incorporated by reference for all purposes. Alternatively, renal fibrosis is induced by treatment with folic acid as described in Yang, HC, et al. Drug Discov Today Dis Models. 2010;7:13-19 and Street, JM, et al. Physiol Rep. 2014;2:e12088, which are incorporated by reference for all purposes.

[0393] Mice are administered antibody treatment following ureteral obstruction. Antibodies are either anti-TREM2 or isotype control. An exemplary antibody administration protocol is shown in Table 10 below.

[0394] [Table 10]

[0395] Administration of an anti-TREM2 antibody results in regression of fibrosis or a slowing of fibrosis progression compared to controls.

[0396] Administration of anti-TREM2 antibodies results in a reduction in the number of TREM2+ macrophages in the scar area compared to controls.

[0397] In addition, kidney weight, histology, and / or hydroxyproline show improvements in the anti-TREM2 antibody treated groups compared to controls.

[0398] heart Cardiac fibrosis is induced by infusion of angiotensin II as described in Kaur, H, et al. Circ Res. 2016;118:1906-1917, Sopel, MJ, et al. Lab Invest. 2011;91:565-578, and Wang, NP, A, et al.. J Renin Angiotensin Aldosterone Syst. 2017;18:1470320317706653, which are incorporated by reference herein for all purposes.

[0399] Mice are treated with angiotensin II followed by antibody therapy. The antibodies are either anti-TREM2 or isotype control. An exemplary antibody administration protocol is shown in Table 11 below.

[0400] [Table 11]

[0401] Administration of an anti-TREM2 antibody results in regression of fibrosis or a slowing of fibrosis progression compared to controls.

[0402] Administration of anti-TREM2 antibodies results in a reduction in the number of TREM2+ macrophages in the scar area compared to controls.

[0403] In addition, heart weight, histology, and / or hydroxyproline show improvements in the anti-TREM2 antibody treated groups compared to controls.

[0404] Example 13: Anti-TREM2 antibody treatment of liver fibrosis Materials and Methods Six to eight week old C57BL / 6J male mice from Jackson Laboratory were divided into five groups. All groups were fed Western chow and sugar water (fructose / glucose mixture) with weekly CCl4 injections (0.2 μl, 100% CCl4 / grams of body weight) for 24 weeks. See Jiao, J., et al, 2012 Dendritic cell regulation of carbon tetrachloride-induced murine liver fibrosis regression. Hepatology 55, 244-255. Three animals each in group 3 (isotype control) and group 4 (anti-TREM2 [Afuc PI-7012, ) were treated for 22 weeks. Obeticholic acid (OCA) was used as a positive control. All mouse groups were left untreated and fed only chow for 12 weeks. Treatment with antibodies or OCA began at week 13. The protocol is provided in Table 12 below.

[0405] [Table 12]

[0406] Animals were weighed once a week before CCl4 injection. Drugs and vehicle were administered intraperitoneally every 5 days or once a day (group 5) for 12 weeks (weeks 13-24). Drug amounts were adjusted for body weight. During the acclimation and drug treatment periods, all animals were examined daily during the dosing period. Any overt behavioral / physiological effects or other relevant observations regarding the animal's condition were recorded.

[0407] Three animals each from the vehicle and anti-TREM2 antibody groups were euthanized at 22 weeks to determine whether to proceed with scRNA analysis. Livers from these animals were weighed, fixed in 10% formalin, sectioned, and stained with H&E and Sirius Red. At the end of the experiment, mouse body weights, liver and spleen weights were recorded. Blood was collected for serum analysis including serum transaminases (ALT and AST), serum total cholesterol and triglycerides, 16 weeks pre-dose, 4 hours post-dose, and termination of anti-TREM2 antibody exposure analysis (data not shown).

[0408] Liver lobes were fixed in 10% formalin, embedded, sectioned, and stained with H&E and Sirius red. General morphology was assessed by a blinded pathologist to assess NAFLD activity score (lobular inflammation, steatosis, balloon-like hepatocytes) and fibrosis stage. Morphometric collagen quantification was determined with Bioquant™ according to the manufacturer's instructions. Snap-frozen liver tissue was prepared for mRNA and protein extraction according to standard protocols. qPCR was performed for the following fibrogenic genes: collagen I, alpha-1 smooth muscle actin, beta-PDGF receptor, MMP2, and TIMP2. Data were normalized to appropriate housekeeping genes. Western blotting for a-SMA and collagen was also performed.

[0409] result As shown in FIG. 9, a significant reduction in liver fibrosis was observed after anti-TREM2 antibody treatment compared to the control. The left panel of FIG. 9 shows H&E staining of livers from mice treated with mIgG2a isotype control antibody or anti-TREM2 antibody. A significant reduction in liver fibrosis was observed in the livers of mice treated with anti-TREM2 antibody. Collagen content in individual mouse livers was also quantified via PSR staining. As shown in the right panel of FIG. 9, treatment with anti-TREM2 antibody significantly reduced collagen compared to untreated mice and isotype control mice at 12 or 24 weeks. As also shown in the right panel of FIG. 9, treatment with anti-TREM2 antibody reduced collagen more than control OCA-treated mice. Tables 13 and 14 provide the PSR-positive area in individual mice treated with TREM2 antibody (Table 13) and OCA (Table 14).

[0410] [Table 13]

[0411] Two of the TREM2 antibody-treated mice had a PSR-positive area less than 0.01, and 10 of the 12 TREM2 antibody-treated mice had a PSR-positive area less than 0.1 (83.3%). In contrast, none of the OCA-treated mice had a PSR-positive area less than 0.01, and only 7 of the 13 OCA-treated mice had a PSR-positive area less than 0.1 (53.8%). Thus, TREM2 antibody treatment was more effective in reducing fibrosis compared to OCA treatment.

[0412] Thus, anti-TREM2 antibody treatment successfully reduced fibrosis in an in vivo liver fibrosis model. References 1.Nimmerjahn,F.& Ravetch,J.V.Divergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding.Science(80-.).310,1510 LP-1512(2005). 2.Ford,J.W.& McVicar,D.W.TREM and TREM-like receptors in inflammation and disease.Curr.Opin.Immunol.21,38-46(2009). 3.Colonna,M.TREMs in the immune system and beyond.Nat.Rev.Immunol.3,445(2003). 4.Takahashi,K.,Rochford,C.D.P.& Neumann,H.Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2.J.Exp.Med.201,647 LP-657(2005). 5.Piccio,L.et al.Blockade of TREM-2 exacerbates experimental autoimmune encephalomyelitis.Eur.J.Immunol.37,1290-1301(2007). 6.Broz,M.L.et al.Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity.Cancer Cell 26,638-652(2017).

[0413] While the present invention has been particularly shown and described with reference to preferred and various alternative embodiments, it will be understood by those skilled in the relevant art that various changes in form and detail may be made therein without departing from the spirit and scope of the invention.

[0414] All references, issued patents, and patent applications cited within the body of this specification are hereby incorporated by reference in their entirety for all purposes.

[0415] array TIFF2024542618000024.tif237165TIFF2024542618000025.tif239165TIFF2024542618000026.tif20716 5TIFF2024542618000027.tif227165TIFF2024542618000028.tif236165TIFF2024542618000029.tif91161

Claims

1. A method of treating a fibrotic disease or condition in a subject, comprising administering an isolated antibody that binds to human TREM2 (SEQ ID NO: 15) and competes with the 37017 antibody (SEQ ID NOs: 31 and 32) for binding to mouse TREM2 (SEQ ID NO: 17); or A method of killing, disabling or depleting TREM2+ bone marrow cells in a subject having a fibrotic disease or condition, comprising contacting the bone marrow cells with an isolated antibody that binds to human TREM2 (SEQ ID NO: 15) and optionally competes with the 37017 antibody (SEQ ID NOs: 31 and 32) for binding to mouse TREM2 (SEQ ID NO: 17).

2. The antibody, a. a CDR-H1 comprising the sequence set forth in SEQ ID NO:9; b. a CDR-H2 comprising the sequence set forth in SEQ ID NO: 10; c. a CDR-H3 comprising the sequence set forth in SEQ ID NO:11; d. a CDR-L1 comprising the sequence set forth in SEQ ID NO: 12; e. a CDR-L2 comprising the sequence set forth in SEQ ID NO: 13; f. CDR-L3 comprising the sequence set forth in SEQ ID NO: 14; The method of claim 1 , comprising:

3. 3. The method of claim 2, wherein the antibody is defucosylated and comprises the VH sequence shown in SEQ ID NO:1, the VL sequence shown in SEQ ID NO:2, and an active human IgG1 Fc region.

4. 3. The method of claim 2, comprising the VH sequence shown in SEQ ID NO:1, the VL sequence shown in SEQ ID NO:2, and a human isotype IgG1 or IgG4 Fc-silent region comprising the N297Q mutation.

5. The antibody, A VH sequence comprising an A to T substitution at position 97 of the sequence set forth in SEQ ID NO:7 and a K to R substitution at position 98 of the sequence set forth in SEQ ID NO:

7. The method of claim 2 , comprising:

6. The method of claim 3 or 4, wherein the antibody comprises a VH sequence as shown in SEQ ID NO: 1, 3, or 5.

7. The method of claim 6, wherein the antibody comprises a VH sequence set forth in SEQ ID NO: 1, 3, or 5, and a VL sequence set forth in SEQ ID NO: 2, 4, or 6.

8. The method of claim 3 or 4, wherein the antibody comprises the VH sequence shown in SEQ ID NO:

1.

9. The method of claim 8, wherein the antibody comprises the VH sequence shown in SEQ ID NO:1 and the VL sequence shown in SEQ ID NO:

2.

10. The method of claim 9, wherein the antibody is the 37012 antibody.

11. 2. The method of claim 1 , wherein the antibody comprises a heavy chain sequence set forth in SEQ ID NO:25 and a light chain sequence set forth in SEQ ID NO:

26.

12. 1. A method of treating a fibrotic disease or condition in a subject, or killing, disabling or depleting TREM2+ bone marrow cells in a subject having a fibrotic disease or condition, comprising administering an isolated antibody that binds to human TREM2 (SEQ ID NO: 15), wherein the antibody: i) optionally competing with the 37017 antibody (SEQ ID NOs: 31 and 32) for binding to mouse TREM2 (SEQ ID NO: 17); ii) comprises a human Fc; The method.

13. A method of treating a fibrotic disease or condition in a subject, or killing, disabling or depleting TREM2+ bone marrow cells in a subject having a fibrotic disease or condition, comprising administering an isolated antibody; The antibody, a. a CDR-H1 comprising the sequence set forth in SEQ ID NO:9; b. a CDR-H2 comprising the sequence set forth in SEQ ID NO: 10; c. a CDR-H3 comprising the sequence set forth in SEQ ID NO:11; d. a CDR-L1 comprising the sequence set forth in SEQ ID NO: 12; e. a CDR-L2 comprising the sequence set forth in SEQ ID NO: 13; f. CDR-L3 comprising the sequence set forth in SEQ ID NO: 14; The method comprising:

14. The antibody, A VH sequence comprising an A to T substitution at position 97 of the sequence set forth in SEQ ID NO:7 and a K to R substitution at position 98 of the sequence set forth in SEQ ID NO:

7. The method of claim 13, comprising:

15. The method of claim 14, wherein the antibody comprises a VH sequence as shown in SEQ ID NO: 1, 3, or 5.

16. The method of claim 15, wherein the antibody comprises a VH sequence set forth in SEQ ID NO: 1, 3, or 5, and a VL sequence set forth in SEQ ID NO: 2, 4, or 6.

17. The method of claim 16, wherein the antibody comprises the VH sequence shown in SEQ ID NO:

1.

18. 18. The method of claim 17, wherein the antibody comprises the VH sequence shown in SEQ ID NO:1 and the VL sequence shown in SEQ ID NO:

2.

19. 19. The method of claim 18, wherein the antibody is 37012 antibody.

20. 14. The method of claim 13, wherein the antibody comprises a heavy chain sequence set forth in SEQ ID NO:25 and a light chain sequence set forth in SEQ ID NO:

26.

21. The antibody has a specific affinity for about 1, 2, 3, 4, or 5×10 as measured by a surface plasmon resonance (SPR) assay. -9 K below M D 2. The method of claim 1, wherein the antibody binds to human TREM2 at

22. 2. The method of any one of the preceding claims, wherein the antibody is capable of specifically killing, depleting or neutralizing unstimulated bone marrow cells, including at least one of TREM2+ myeloid cells, optionally TREM2+ macrophages, TREM2+CD9+ macrophages, macrophages, scar-associated macrophages (SAM), dendritic cells, neutrophils, or monocytes.

23. 2. The method of any one of the preceding claims, wherein the antibody has antibody-dependent cell-mediated cytotoxicity (ADCC) activity.

24. 2. The method of any one of the preceding claims, wherein the antibody has antibody-mediated phagocytosis (ADCP) activity.

25. 2. The method of any one of the preceding claims, wherein the antibody has complement dependent cytotoxicity (CDC) activity.

26. 2. The method of any one of the preceding claims, wherein the antibody is at least one of a monoclonal antibody, a neutral antibody, an antagonistic antibody, an agonistic antibody, a polyclonal antibody, an IgG1 antibody, an IgG3 antibody, a defucosylated antibody, a bispecific antibody, a human antibody, a chimeric antibody, a full-length antibody, and antigen-binding fragments thereof.

27. 2. The method of any one of the preceding claims, wherein the antibody is a monoclonal antibody.

28. 2. The method of any one of the preceding claims, wherein the antibody is multispecific.

29. 2. The method of any one of the preceding claims, wherein the antibody is defucosylated.

30. 2. The method of any one of the preceding claims, wherein the antibody is an antigen-binding fragment thereof, a Fab, a Fab', a F(ab')2, an Fv, a scFv, a (scFv)2, a single-chain antibody molecule, a dual variable domain antibody, a single variable domain antibody, a linear antibody, or a V domain antibody.

31. 2. The method of any one of the preceding claims, wherein the antibody comprises a scaffold, optionally wherein the scaffold is an Fc, optionally a human Fc.

32. 2. The method of any one of the preceding claims, wherein the antibody is of an isotype selected from IgG, IgA, IgD, IgE, and IgM.

33. 10. The method of any one of the preceding claims, wherein the antibody is of an IgG isotype, comprising a subclass selected from IgG1, IgG2, IgG3, and IgG4.

34. 2. The method of any one of the preceding claims, wherein the antibody is an IgG1 antibody.

35. 2. The method of any one of the preceding claims, wherein the Fc comprises one or more modifications that result in increased half-life, increased ADCC activity, increased ADCP activity, or increased CDC activity compared to an Fc that does not comprise said one or more modifications.

36. 2. The method of any one of the preceding claims, wherein the Fc binds to an Fcγ receptor selected from the group consisting of FcγRI, FcγRIIa, FcγRIIb, FcγRIIc, FcγRIIIa, and FcγRIIIb.

37. 2. The method of any one of the preceding claims, wherein the antibody binds to the extracellular domain of TREM2 on TREM2+ myeloid cells.

38. 2. The method of any one of the preceding claims, wherein the antibody binds to the extracellular domain of TREM2 on myeloid cells, the myeloid cells are unstimulated myeloid cells that are CD45+, HLA-DR+, CD11c+, CD14+, and BDCA3-, and the antibody kills, disables, or depletes the unstimulated myeloid cells via ADCC, CDC, and / or ADCP to a level lower than the level of unstimulated myeloid cells present in the fibrotic disease prior to contacting the unstimulated myeloid cells with the antibody, the unstimulated myeloid cells are present in a population of immune cells that includes stimulatory myeloid cells that are CD45+, HLA-DR+, CD14-, CD11c+, BDCA1-, and BDCA3+ and the unstimulated myeloid cells, and wherein killing, disabling, or depleting the unstimulated myeloid cells treats the fibrotic disease.

39. 2. The method of any one of the preceding claims, wherein the antibody has antibody-dependent cell-mediated cytotoxicity (ADCC) activity.

40. 2. The method of any one of the preceding claims, wherein the antibody has complement dependent cytotoxicity (CDC) activity.

41. 2. The method of any one of the preceding claims, wherein the antibody has antibody-mediated phagocytosis (ADCP) activity.

42. 2. The method of any one of the preceding claims, wherein the antibody has receptor ligand blocking activity, agonism activity, or antagonism activity.

43. 10. The method of any one of the preceding claims, wherein the subject is a human.

44. 2. The method of any one of the preceding claims, wherein the TREM2+ bone marrow cells comprise at least one of TREM2+ macrophages, TREM2+CD9+ macrophages, macrophages, scar-associated macrophages (SAMs), dendritic cells, tumor-associated macrophages (TAMs), neutrophils, or monocytes.

45. 10. The method of any one of the preceding claims, wherein the fibrotic disease or condition is a liver disease.

46. 2. The method of any one of the preceding claims, wherein the liver disease is NAFLD.

47. 10. The method of any one of the preceding claims, wherein the liver disease is NASH.

48. 2. The method of any one of the preceding claims, wherein the liver disease is selected from the group consisting of fibrosis, NAFL, cirrhosis, or liver cancer.

49. 10. The method of any one of the preceding claims, wherein the liver disease is a fatty liver disease selected from the group consisting of fatty liver disease resulting from obesity, fatty liver disease resulting from diabetes, fatty liver disease resulting from insulin resistance, fatty liver disease resulting from hypertriglyceridemia, abetalipoproteinemia, glycogen storage disease, Weber-Christian disease, Wolman disease, acute fatty liver of pregnancy, and lipoatrophy.

50. 2. The method of any one of the preceding claims, wherein said contacting enhances an immune response in the subject.

51. 51. The method of claim 50, wherein the enhanced immune response is an adaptive immune response.

52. 51. The method of claim 50, wherein the enhanced immune response is an innate immune response.

53. 13. The method of any one of the preceding claims, wherein the subject has previously undergone, is concurrently undergoing, or will subsequently undergo, immunotherapy.

Citation Information

Patent Citations

  • US10,836,828

  • Modulation of stimulatory and non-stimulatory myeloid cells

    WO2016049641A1

  • Anti-TREM2 antibodies and uses thereof

    WO2017058866A1